



**Vaccines and Global Health: The Week in Review**  
**21 September 2024 :: Issue 767**  
**Center for Vaccine Ethics & Policy (CVEP)**

*This weekly digest targets news, events, announcements, articles and research in the vaccine and global health ethics and policy space and is aggregated from key governmental, NGO, international organization and industry sources, key peer-reviewed journals, and other media channels. This summary proceeds from the broad base of themes and issues monitored by the Center for Vaccine Ethics & Policy in its work: it is not intended to be exhaustive in its coverage.*

*Vaccines and Global Health: The Week in Review is published as a PDF and scheduled for release each Saturday [U.S.] at midnight [0000 GMT-5]. The PDF is posted at <https://centerforvaccineethicsandpolicy.net>. This blog allows full text searching of over 27,000 entries.*

*Comments and suggestions should be directed to*

*David R. Curry, MS*

*Editor and*

*Executive Director Center for Vaccine Ethics & Policy*

*[david.r.curry@centerforvaccineethicsandpolicy.org](mailto:david.r.curry@centerforvaccineethicsandpolicy.org)*

***Request email delivery of the pdf:*** *If you would like to receive the PDF of each edition via email [Constant Contact], please send your request to [david.r.curry@centerforvaccineethicsandpolicy.org](mailto:david.r.curry@centerforvaccineethicsandpolicy.org).*

***Support this knowledge-sharing service:*** *Your financial support helps us cover our costs and to address a current shortfall in our annual operating budget. Click [here](#) to donate and thank you in advance for your contribution.*

***Contents [click to move among sections]***

*:: [Milestones, Perspectives](#)*

*:: [WHO](#)*

*:: [Organization Announcements](#)*

*:: [Journal Watch](#)*

*:: [Pre-Print Servers](#)*

*:: [Think Tanks](#)*

## ***Milestones, Perspectives***

.....  
.....

### **Mpox - PHEIC**

#### **Gavi Signs Agreement with Bavarian Nordic to Rapidly Secure 500,000 Doses of Mpox Vaccines for Africa**

*:: The advance purchase agreement (APA) will be funded by Gavi's First Response Fund, a mechanism created after the COVID-19 pandemic to ensure rapid access to scarce vaccine supplies in future health emergencies.*

*:: Availability of all 500,000 doses has been secured for 2024.*

COPENHAGEN, Denmark and GENEVA, Switzerland, September 18, 2024 – Bavarian Nordic A/S (OMX: BAVA) and Gavi, the Vaccine Alliance today announced an advance purchase agreement (APA) to secure 500,000 doses of the MVA-BN® mpox vaccine (marketed as JYNNEOS® or IMVANEX®) to be supplied to countries in Africa impacted by the mpox outbreak. The doses will be for delivery in 2024. **The vaccines will be funded by Gavi's First Response Fund, a new financial mechanism created in June 2024 to make cash rapidly available to purchase vaccines in health emergencies...**

.....

#### **Global Fund Provides Nearly US\$10 Million for DRC's Mpox Response**

18 September 2024

At the request of the government of the Democratic Republic of the Congo (DRC), the Global Fund to Fight AIDS, Tuberculosis and Malaria (the Global Fund) is supporting the country with US\$9.5 million for its emergency mpox response in six of the highest transmission provinces: Equateur, Sud-Ubangui, Sankuru, Tshopo, Sud-Kivu, Nord-Kivu, as well as in Kinshasa, a province with a high population density and 17 million people...

.....

#### **NIH releases mpox research agenda**

*Plan will advance knowledge of virus biology to improve detection, treatment and prevention.*

Tuesday, September 17, 2024

As part of the U.S. government response to the current mpox outbreak(link is external), the National Institutes of Health's (NIH) National Institute of Allergy and Infectious Diseases (NIAID) has released an update on its priorities for mpox research.

The NIAID mpox research agenda focuses on four key objectives:

- increasing knowledge about the biology of all clades—also known as strains—of the virus that causes mpox, including how the virus is transmitted and how people's immune systems respond to it;
- evaluating dosing regimens of current vaccines to stretch the vaccine supply and developing novel vaccine concepts;
- advancing existing and novel treatments, including antivirals and monoclonal antibodies; and
- supporting strategies for detecting the virus to facilitate clinical care and epidemiological surveillance...

NIAID continues to collaborate closely with U.S. and international partners to reduce the impact of the current mpox outbreak and safeguard public health globally. NIAID will leverage both its domestic and international research infrastructures to achieve the Institute's research objectives.

:: [NIAID Research Agenda for 2024 Mpox – September 2024](#)

.....

### [\*\*WMA calls for governments' cooperation in mpox public health emergency\*\*](#)

*Press Release 19.08.2024*

The World Medical Association urges governments to adhere to the principles of the **2023 UN Political Declaration on Pandemic Prevention, Preparedness, and Response (PPPR)**, in response to the designation by the WHO of mpox as a public health emergency of international concern (PHEIC).

"As we face the mpox crisis, WMA calls on countries to enhance regional and international cooperation to deliver a united, multisector and high-level approach. **We ask governments to guarantee the affordable, equitable, and timely access to mpox medical countermeasures. And so that no one is left behind during the mpox public health emergency**, WMA encourages national governments to provide universal access to quality health services, without financial hardship, for everyone and particularly for those in vulnerable situations," said Dr. Lujain AlQodmani, President of the World Medical Association.

"The challenges that the world currently faces in responding to this outbreak further underline the importance of improving global solidarity. This is key to ensure that all countries contribute to supporting regions where outbreaks are occurring, to protect the health of the affected populations and prevent their international spread," continued Dr. AlQodmani.

**The realization of these principles through the amended International Health Regulations (IHR) and, hopefully, a new Pandemic Accord are critical for our future capacity to do better.** Civil society organizations like the WMA and its worldwide membership base can actively contribute to operationalizing those principles.

The WMA also calls on countries to continue to invest in the development and support of a skilled health workforce, fundamental to building strong, resilient health systems which are better prepared for pandemics and public health emergencies.

.....

.....

## **Cholera**

### [\*\*Multi-country outbreak of cholera, External situation report #18 - 18 September 2024\*\*](#)

Edition 18

18 September 2024 | Emergency Situational Updates

#### *Overview*

From 1 January 2024 to 25 August 2024, a cumulative total of 371 517 cholera cases and 2527 deaths were reported from 28 countries across five WHO regions, with the Eastern Mediterranean Region recording the highest numbers, followed by the African Region, the Region of the Americas, the South-East Asia Region, and the European Region. No outbreaks were reported in the Western Pacific Region during this time.

WHO classified the global resurgence of cholera as a grade 3 emergency in January 2023, the highest internal level for emergencies in WHO. Based on the number of outbreaks and their geographic

expansion, alongside the shortage of vaccines and other resources, WHO continues to assess the risk at the global level as very high and the event remains classified as a grade 3 emergency.

Cholera upsurge (2021-present): <https://www.who.int/emergencies/situations/cholera-upsurge/>

[Excerpt]

#### ... **Vaccination**

- Fifteen new requests were received in 2024 from Bangladesh, Comoros, Ethiopia (3), Kenya, Mozambique, Myanmar, Nigeria, Somalia, Sudan (2), Yemen, Zambia, and Zimbabwe, collectively seeking 37 million doses. Nine were approved, one was not approved, one was cancelled, and one is pending a decision from the International Coordinating Group (ICG) on Vaccine Provision. One additional country is considering submitting request.
- Since the start of 2024, seven countries (Comoros, Ethiopia, Mozambique, Somalia, Sudan, Zambia, and Zimbabwe) have carried out ten reactive vaccination campaigns in response to cholera outbreaks, targeting a total of 12 million people.
- Given the current context of outbreaks and limited vaccine availability, only single-dose vaccination courses have been validated and utilized in these reactive campaigns.
- The constrained supply of OCVs is severely impacting the capacity to carry out preventive vaccination campaigns.
- The limited global stockpile of OCVs underscores the need for increased production and strategic stockpile management to ensure that both reactive and preventive needs are adequately met.

.....  
.....

#### **Pandemic Accord**

##### **Governments progress on negotiations for a pandemic agreement to boost global preparedness for future emergencies**

20 September 2024 *News release*

Government-led negotiations on the world's first agreement to protect people from future pandemics made significant progress during the latest round of discussions that ended today at the World Health Organization (WHO).

Substantive progress on the draft agreement, increased involvement of civil society and non-State actors, and a commitment by all parties to sustain momentum towards a pandemic agreement were hallmarks of the 11th meeting of the Intergovernmental Negotiating Body (INB), which comprises the 194 member governments of WHO, and ran from 9-20 September in Geneva. Negotiators will resume discussions, at a 12th round, from 4-15 November.

Dr Tedros Adhanom Ghebreyesus, WHO Director-General, praised the "collective commitment" shown by governments and other stakeholders to conclude the pandemic agreement, and an urgent need to do so in light of the persistent threat shown by viruses with pandemic potential...

Each day during the past two weeks of discussions, INB relevant stakeholders joined negotiators for updates on progress and next steps, the latest version of the draft agreement reflecting the latest government proposals, and to offer suggestions. Detailed interactive dialogues were held during the week prior on critical subjects and publicly broadcast...

**Webcast: Specific sessions can be viewed by selecting them in the menu field next to the player.**

.....



## Featured Journal Content

### The Lancet

*Correspondence* *Online first* September 20, 2024

#### [An urgent case for measles vaccination in Gaza](#)

Ronald Waldman<sup>a</sup> Robert Steinglass<sup>b</sup> Phillip Nieburg<sup>c</sup>

In response to the identification of circulating vaccine-derived poliovirus type 2 in wastewater in Gaza, followed by a single confirmed case of paralytic poliomyelitis in a young child, the first round of an oral polio vaccination campaign targeting children (aged  $\leq 10$  years) is underway and has, as of Sept 16, 2024, been highly successful.<sup>1</sup> The detailed planning, hard work, and heroic dedication of all those involved, under the most trying of circumstances, are evident. A second round of vaccination is planned for the end of September, 2024.<sup>1</sup> Now that an operational platform is in place, we believe that the second round should include vaccination against measles, which has consistently been the deadliest vaccine-preventable disease in humanitarian emergencies.

Measles is among the most highly infectious diseases known and is symptomatic in nearly 100% of exposed, non-immune individuals. High population density, inadequate shelter, poor sanitation, and undernutrition are all major risk factors for infection, severity, and death, and all are features of the deplorable conditions for those people living in Gaza. The imminent arrival of cooler temperatures adds to the urgency to vaccinate against this disease, which can cause the death of up to 15% of those infected.<sup>2</sup>

As with poliovirus, reported vaccination coverage for measles has been high in Gaza, but has been falling. With the collapse of the health-care system, many children being vaccinated against measles within the past year is unlikely. Treatment of complications of measles will be difficult, if not impossible. Due to the very rapid rate of transmission and the dangerous environment, vaccinating after an outbreak occurs might be too late—prevention is by far the best, if not the only, life-saving measure.

Unlike poliovirus, the measles vaccine is delivered by injection. However, the delivery of vaccines by both oral and injectable routes has been done successfully in the past when conflicts have been temporarily paused to allow children to be vaccinated. Since the current polio vaccination campaign is operating from multiple fixed sites and not house-to-house, the delivery of measles vaccine to a restricted target population (possibly children aged 6–23 months) is feasible with some additional training of staff in triage, crowd control, risk communication, and safe injection techniques.

Those involved in organising and implementing the current vaccination campaign (such as Gazan health authorities, UN agencies, and non-governmental organisations) are justified in restricting the focus of the current operation. Under the circumstances, any unwarranted expansion or add-on of unnecessary interventions can result in operational complications that could jeopardise the outcome.

There is good reason that, for nearly 50 years, mass measles vaccination campaigns have become a standard early intervention in conflict and other humanitarian settings;<sup>3,4</sup> the risk of a measles outbreak and accompanying high mortality is just too great. As Steinglass and colleagues<sup>5</sup> have stated, to forgo measles vaccination of the children of Gaza would be a failure to learn from the past, a missed opportunity, and risks leading to an unacceptable public health tragedy.

*We declare no competing interests.*

*Editorial note: The Lancet Group takes a neutral position with respect to territorial claims in published text.*

.....  
.....

## Polio – PHEIC

### Polio this week as of 18 September 2024 - GPEI

**:: Gaza: first round vaccination response completed:** in Gaza, the first round of an emergency vaccination campaign conducted in three phases completed on 12 September. The 12-day campaign provided novel oral polio vaccine type 2 (nOPV2) to around 560,000 children under the age of ten, following meticulous planning and coordination. The campaign was conducted by the Palestinian Ministry of Health, in collaboration with WHO, UNICEF, UNRWA and partners. The second round is planned for in approximately 4-6 weeks' time. [More](#).

**:: Sahel and Lake Chad Basin countries coordinate joint polio eradication plan:** in a significant move to combat the ongoing challenge of variant poliovirus transmission in Central and West Africa, Ministers of Health from the Lake Chad Basin countries and Sahel sub-region have published this week a comprehensive cross-border coordination plan for 2024/2025. This critical initiative aims to bolster joint efforts to eradicate polio and prevent its spread across national borders, ensuring a safer and healthier future for millions of children. [More](#).

### ***Summary of new polioviruses this week, cases and positive environmental isolates:***

- Afghanistan: one WPV1 case and five WPV1-positive environmental samples
- Pakistan: 30 WPV1-positive environmental samples
- Cameroon: two cVDPV2 cases
- Chad: two cVDPV2-positive environmental samples
- Niger: one cVDPV2-positive environmental sample
- Nigeria: four cVDPV2 cases
- South Sudan: two cVDPV2-positive environmental samples
- Zimbabwe: two cVDPV2-positive environmental samples

.....  
.....

### Gates Foundation Report Calls for Targeted Global Health Spending to Save Millions of Children from Malnutrition and Disease

*New modeling shows 40 million more children will suffer from hunger's worst effects by 2050 due to climate change, but immediate action could instead boost health, spur economic growth*

SEATTLE (September 17, 2024) – In its eighth annual [Goalkeepers](#) report released today, the Bill & Melinda Gates Foundation urged world leaders to increase global health spending where it is needed most in order to boost children's health and [nutrition](#), especially in the face of the global climate crisis.

**The Goalkeepers report, "A Race to Nourish a Warming World," projects that without immediate global action, climate change will condemn an additional 40 million children to stunting and 28 million more to wasting between 2024 and 2050.** Scaling up solutions now can avoid this outcome, while also building [resilience to climate change](#) and spurring much-needed economic growth.

In 2023, the World Health Organization estimated that 148 million children experienced stunting, a condition where children don't grow to their full potential mentally or physically, and 45 million children experienced wasting, a condition where children become weak and emaciated, leaving them at much

greater risk of developmental delays and death. These are the most severe and irreversible forms of chronic and acute malnutrition...

"Today, the world is contending with more challenges than at any point in my adult life: inflation, debt, new wars. Unfortunately, aid isn't keeping pace with these needs, particularly in the places that need it the most," writes report author [Bill Gates](#), co-chair of the Bill & Melinda Gates Foundation. "I think we can give global health a second act—even in a world where competing challenges require governments to stretch their budgets."

**According to Gates, malnutrition is "the world's worst child health crisis," and climate change is only making it worse. Amidst this crisis, Gates calls for maintaining global health funding; immediately addressing the growing threat of child malnutrition by supporting the Child Nutrition Fund, a new platform that coordinates donor financing for nutrition; and governments fully funding the established institutions that have proven effective at protecting millions of lives each year. These institutions include Gavi, the Vaccine Alliance, which is due to hold its next funding replenishment in 2025; and the Global Fund to Fight AIDS, Tuberculosis and Malaria, which is expected to also hold its replenishment next year.**

"If we do these three things, we won't just usher in a new global health boom and save millions of lives—we'll also prove that humanity can still rise to meet our greatest challenges," Gates writes.

**The report also shines a light on the catastrophic economic costs of malnutrition and highlights solutions that can help mitigate them.** According to the World Bank, the cost of undernutrition is US\$3 trillion in productivity loss every year, because malnutrition stunts people's physical and cognitive abilities. In low-income countries, that loss ranges from 3% to 16% (or more) of GDP, which amounts to a permanent 2008-level global recession every year.

### ***Proven Tools Exist Today***

"The best way to fight the impacts of climate change is by investing in nutrition...Malnutrition makes every forward step our species wants to take heavier and harder," Gates writes. "But the inverse is also true. If we solve malnutrition, we make it easier to solve every other problem. We solve extreme poverty. [Vaccines](#) are more effective. And deadly diseases like malaria and pneumonia become far less fatal."

The report highlights proven tools that are helping solve malnutrition, building people's resilience to the worst impacts of climate change, and further driving down childhood deaths. They include:

- **New agricultural technologies that are producing up to two to three times more milk and safer milk, which can prevent millions of cases of child stunting by 2050.**
  - Modeling shows that in India, [Ethiopia](#), [Kenya](#), [Nigeria](#), and Tanzania, these technologies can prevent 109 million cases of child stunting by 2050.
- **Efforts to scale up new ways of fortifying pantry staples, such as salt and bouillon cubes, can reduce millions of cases of anemia and prevent deaths due to neural tube defects.**
  - In Ethiopia, a new process to fortify salt with iodine and folic acid could lead to a 4% reduction in anemia and could eliminate up to 75% of all deaths and stillbirths due to neural tube defects.
  - In Nigeria, fortifying bouillon cubes with iron, folic acid, zinc, and vitamin B12 could avert up to 16.6 million cases of anemia and up to 11,000 deaths from neural tube defects.
- **Efforts to provide a high-quality prenatal vitamin for pregnant women could save almost half a million lives and improve birth outcomes for 25 million babies by 2040.**
  - Adopting multiple micronutrient supplements (MMS) costs as little as \$2.60 for an entire pregnancy in all low- and middle-income countries.



The report also highlights how promising new research into the microbiome can improve people's health. **Studies indicate that better gut health can help children absorb nutrients, develop strong immune systems, and grow as they should to thrive.** A deeper understanding of gut health, Gates writes, has the potential to change not just how the world treats malnutrition but also overnutrition, which impacts wealthy countries...

.....  
.....

### ***Contents [click to move among sections]***

:: [\*Milestones, Perspectives\*](#)  
:: [\*WHO\*](#)  
:: [\*Organization Announcements\*](#)  
:: [\*Journal Watch\*](#)  
:: [\*Pre-Print Servers\*](#)

.....  
.....

### **WHO & Regional Offices** [to 21 Sep 2024]

<https://www.who.int/news>

[\*Selected News/Announcements/Statements\*](#)

20 September 2024 *News release*

[\*\*Governments progress on negotiations for a pandemic agreement to boost global preparedness for future emergencies\*\*](#)

19 September 2024 *News release*

[\*\*WHO at UNGA: Call for urgent, high-level action to address global scourge of antimicrobial resistance\*\*](#)

17 September 2024 *News release*

[\*\*"Get it right, make it safe!": WHO highlights safe diagnosis during global campaign for patient safety\*\*](#)

.....

### **WHO Regional Offices**

[\*Selected Press Releases, Announcements\*](#)

#### **WHO African Region**

:: 21 September 2024

[\*\*Devastating West and Central Africa floods affect over 4 million people, raise health risks\*\*](#)

:: 20 September 2024

[\*\*WHO delivers 33.5 metric tonnes of medical supplies to the Democratic Republic of the Congo\*\*](#)

:: 20 September 2024

[\*\*Ensuring primary health services for displaced people\*\*](#)

:: 18 September 2024

[\*\*Three Central African countries commit to global eradication of Guinea-worm disease\*\*](#)

#### **WHO Region of the Americas PAHO**

:: 20 Sep 2024



## **[PAHO and Africa CDC strengthen collaboration to address access to essential medicines and vaccines](#)**

Washington D.C., USA 20 September 2024 – The Pan American Health Organization today signed an agreement with the Africa Centres for Disease Control and Prevention (Africa CDC) to collaborate on equitable access to vaccines, medicines and other strategic health technologies. Under the shared vision, the two organizations will leverage their...

:: 19 Sep 2024

## **[PAHO and MSD launch project to improve maternal health in Latin America](#)**

Interventions aim to accelerate the reduction of maternal mortality and directly benefit thousands of women in Honduras and Peru, with wider indirect benefits for more than half a million women of childbearing age from both countries Washington D.C., September 19, 2024 (PAHO) – The Pan American Health Organization (PAHO) and MSD, known as Merck...

## **[WHO South-East Asia Region SEARO](#)**

:: 19 September 2024 News release

## **[WHO calls for adolescent responsive health systems, emphasizes on triple dividend benefit](#)**

:: 19 September 2024 News release

## **[Jordan becomes first country to receive WHO verification for eliminating leprosy](#)**

## **[WHO European Region EURO](#)**

*No new digest content identified.*

## **[WHO Eastern Mediterranean Region EMRO](#)**

*No new digest content identified.*

## **[WHO Western Pacific Region](#)**

*No new digest content identified.*

.....

## **[WHO - Emergency situation reports](#)**

*Latest WHO official reports for emergency situations. Latest WHO official reports for emergency situations.*

## **[Sudan conflict and refugee crisis, Multi-country External Situation Report #4, covering the reporting period August 2024](#)**

## **[Multi-country outbreak of cholera, External situation report #18 - 18 September 2024](#)**

.....

## **[Disease Outbreak News \(DONs\)](#)**

*Latest WHO Disease Outbreak News (DONs), providing information on confirmed acute public health events or potential events of concern.*

## **[20 September 2024 | Avian Influenza A\(H9N2\) - Ghana](#)**

.....

## **[Weekly Epidemiological Record](#)**

<https://www.who.int/publications/journals/weekly-epidemiological-record>

**Vol. 99, No. 38, pp. 523–544 20 September 2024**

PDF: <https://iris.who.int/bitstream/handle/10665/378987/WER9938-eng-fre.pdf>

:: 37th Meeting of the International Task Force for Disease Eradication, 11–12 June 2024  
:: Progress towards poliomyelitis eradication – Pakistan, January 2023–June 2024

.....

## **New WHO Publications**

<https://www.who.int/publications/i>

*Selected*

19 September 2024

### **[Technical consultation on the WHO Antimicrobial Resistance Diagnostic Initiative](#)**

18 September 2024

### **[WHO global technical consultation on public health and social measures during health emergencies: report...](#)**

*Overview*

World Health Organization (WHO) held its 2nd global technical consultation on public health and social measures (PHSM) during health emergencies from 21 to 23 November 2023 to accelerate the use of PHSM as essential countermeasures for epidemic and pandemic preparedness and prevention. The meeting brought together 87 experts from various sectors in more than 30 countries, representing Member States and academia, as well as civil society and international organizations. During the consultation, experts identified critical initial actions to be taken by decision-makers, researchers and communities to facilitate a timely, equitable and context-specific PHSM response to outbreaks of infectious diseases with epidemic and pandemic potential. The resulting compendium encompasses critical initial actions on PHSM for viruses carried by the Aedes mosquito, zoonotic spillover, and novel respiratory viruses with pandemic potential. Experts noted the urgency to advance the more systematic integration of PHSM into existing emergency preparedness and response frameworks. The strategic positioning of PHSM as critical countermeasures alongside vaccines, therapeutics and other medical countermeasures will increase the recognition of their complementary roles in the fight against epidemics and pandemics. The conclusions of the consultation underscore the need for maintaining political and strategic focus on PHSM to maximize their full potential in saving lives and protecting the livelihoods of affected communities during future health emergencies.

16 September 2024

### **[Addressing gender inequalities in national action plans on antimicrobial resistance](#)**

.....

.....

## **USA – HHS, FDA, CDC**

### **HHS**

*News*

*No new digest content identified.*

### **FDA**

*Press Announcements*

*News*

### **[FDA Approves Nasal Spray Influenza Vaccine for Self- or Caregiver-Administration First Influenza Vaccine That Does Not Need to be Administered by a Health Care Provider](#)**

September 20, 2024

### **FDA VRBPAC**

*Advisory Committee Calendar*  
*No new digest content identified.*

**CDC/ACIP [U.S.]** [to 21 Sep 2024]  
<http://www.cdc.gov/media/index.html>  
*Latest News*  
*No new digest content identified.*

**ACIP Meetings**  
*Next ACIP Meeting*  
October 23-24, 2024

**MMWR Weekly**  
<https://www.cdc.gov/mmwr/index2023.html>  
**September 19, 2024 / No. 37**  
[PDF of this issue](#)

- [Wastewater Surveillance for Influenza A Virus and H5 Subtype Concurrent with the Highly Pathogenic Avian Influenza A\(H5N1\) Virus Outbreak in Cattle and Poultry and Associated Human Cases — United States, May 12–July 13, 2024](#)
- [Use of COVID-19 Vaccines for Persons Aged ≥6 Months: Recommendations of the Advisory Committee on Immunization Practices — United States, 2024-2025](#)
- [Notes from the Field: Support for Wastewater Monitoring and Influence on Protective Behavioral Intentions Among Adults — United States, July 2024](#)

.....  
.....

## Europe

**European Medicines Agency [EMA]**  
<https://www.ema.europa.eu/en/news>  
*News & Press Releases*

### [Meeting highlights from the Committee for Medicinal Products for Human Use \(CHMP\) 16-19 September 2024](#)

8 new medicines recommended for approval; another 12 medicines recommended for extension of their therapeutic indications  
20 September 2024

...The CHMP adopted a positive opinion for Penbraya (meningococcal groups A, C, W, Y conjugate and group B vaccine (recombinant, adsorbed)), a vaccine indicated for immunisation against invasive disease caused by *Neisseria meningitidis*, a Gram-negative bacterium, often referred to as meningococcus, that colonizes the upper respiratory tract, which, in some individuals, can cause serious, life-threatening invasive meningococcal disease...

### [EMA recommends extending indication of mpox vaccine to adolescents](#)

Vaccine assessment can support African regulators in fight against ongoing outbreak  
19 September 2024

**European Centre for Disease Prevention and Control**  
<https://www.ecdc.europa.eu/en>  
*News/Updates/Reports/Publications [Selected]*

[Epidemiological update, week 37/2024: Mpox due to monkeypox virus clade I](#)  
17 Sep 2024

*Public health guidance*

**Reporting Protocol for integrated respiratory virus surveillance, version 1.7**

18 Sep 2024

This Reporting Protocol describes data collection for influenza, COVID-19, and other respiratory viruses (such as RSV or new viruses of public health concern) in the EU/EEA and wider WHO European Region. Data collection is integrated for most datasets in line with the operational considerations for respiratory virus surveillance in Europe.

.....  
.....

**Africa CDC** [to 21 Sep 2024]

<https://africacdc.org/>

*Press Releases, Statements [Selected]*

*Press Releases*

**PAHO and Africa CDC strengthen collaboration to address access to essential medicines and vaccines**

Washington D.C., USA 20 September 2024 – The Pan American Health Organization today signed an agreement with the Africa Centres for Disease Control and Prevention (Africa CDC) to collaborate on equitable access to vaccines, medicines and other strategic health technologies. Under the shared vision, the two organizations will leverage their respective expertise, including through PAHO's Regional Revolving Funds, to strengthen regional regulatory, innovation and production mechanisms, and feed into the development of the African pooled procurement mechanism and promotion of local manufacturing of essential medicines, vaccines and public health supplies for Africa and the Americas.

The organizations will also collaborate to advance research, innovation and digital transformation of health systems to respond to current and emerging public health challenges, as well as to enhance prevention, preparation and response to health emergencies...

*Press Releases*

**Africa CDC congratulates Japan and DRC on the Signing of Notes for a donation of Mpox Vaccines**

KINSHASA, 18 September – Africa CDC congratulates the Government of Japan and the Government of the Democratic Republic of the Congo (DRC) on the agreement to donate Lc16 Mpox vaccines, along with specialized inoculation needles. A signing ceremony in Kinshasa formalized the exchange of notes for this crucial grant, marking a significant milestone in the cooperation between the two governments.

This donation comes at a pivotal time as the DRC continues to battle a regional Mpox outbreak, with cases rising significantly since November 2023. Japan's contribution is a crucial boost as the Mpox vaccine is the only shot currently approved for children...

*Media Advisory*

**Special Press Briefing on the Mpox Outbreak and other Health Emergencies in Africa**

16 September 2024

.....  
.....

**China CDC**

<http://www.chinacdc.cn/en/>

**National Health Commission of the People's Republic of China** [to 21 Sep 2024]

<http://en.nhc.gov.cn/>

News

No new digest content identified.

**National Medical Products Administration – PRC** [to 21 Sep 2024]

<http://english.nmpa.gov.cn/>

News

No new digest content identified.

**China CDC**

**CCDC Weekly Reports: Current Volume (6)**

**2024-09-20 / No. 38 HIGH-QUALITY DEVELOPMENT OF DISEASE PREVENTION AND CONTROL ISSUE**

[View PDF of this issue](#)

- [Perspectives: Advancing China's Disease Control and Prevention System: A Strategic Roadmap for High-Quality Development](#)
- [Perspectives: China's Initiatives and Achievements in Enhancing the Professional Capabilities of CDCs](#)
- [Perspectives: Strengthening Organizational Support Is Essential for the High-Quality Development of Disease Prevention and Control Initiatives](#)
- [Perspectives: Strengthening the Construction of the Talent Team and Promoting the High-Quality Development of Disease Prevention and Control](#)
- [Notifiable Infectious Diseases Reports: Reported Cases and Deaths of National Notifiable Infectious Diseases — China, July 2024\\*](#)

.....

.....

***Contents [click to move among sections]***

:: [Milestones, Perspectives](#)

:: [WHO](#)

:: [Organization Announcements](#)

:: [Journal Watch](#)

:: [Pre-Print Servers](#)

.....

.....

***Organization Announcements***

**Paul G. Allen Frontiers Group** [to 21 Sep 2024]

<https://alleninstitute.org/news-press/>

News

**[Allen Institute for Immunology unveils landmark Human Immune Health Atlas](#)**

09.19.2024

*Comprehensive dataset maps the landscape of healthy immune cells across the human lifespan*

**BMGF - Gates Foundation** [to 21 Sep 2024]

<https://www.gatesfoundation.org/ideas/media-center>

Press Releases & Statements

**[Gates Foundation Report Calls for Targeted Global Health Spending to Save Millions of Children from Malnutrition and Disease](#)**

*New modeling shows 40 million more children will suffer from hunger's worst effects by 2050 due to climate change, but immediate action could instead boost health, spur economic growth*  
SEATTLE (September 17, 2024)

**Bill & Melinda Gates Medical Research Institute** [to 21 Sep 2024]

<https://www.gatesmri.org/news>

*The Bill & Melinda Gates Medical Research Institute is a non-profit biotech organization. Our mission is to develop products to fight malaria, tuberculosis, and diarrheal diseases—three major causes of mortality, poverty, and inequality in developing countries. The world has unprecedented scientific tools at its disposal; now is the time to use them to save the lives of the world's poorest people*

*News: Articles and Publications*

*No new digest content identified.*

**CARB-X** [to 21 Sep 2024]

<https://carb-x.org/>

*News*

*No new digest content identified.*

**CEPI – Coalition for Epidemic Preparedness Innovations** [to 21 Sep 2024]

<http://cepi.net/>

*CEPI News*

*Blog*

**[The Global Pandemic Preparedness Summit 2024: Outcomes Report](#)**

Report summarises discussions and recommendations to emerge from the global Summit  
17 Sep 2024

*Blog*

**[Navigating Existential Risks: Insights from Dr. Richard Hatchett](#)**

16 Sep 2024

**CIOMS – COUNCIL FOR INTERNATIONAL ORGANIZATIONS OF MEDICAL SCIENCES** [to 21 Sep 2024]

<https://cioms.ch/>

*News; Publications; Events*

*No new digest content identified.*

**DARPA – Defense Advanced Research Projects Agency [U.S.]** [to 21 Sep 2024]

<https://www.darpa.mil/news>

*News*

*No new digest content identified.*

**Duke Global Health Innovation Center** [to 21 Sep 2024]

<https://dukeghic.org/>

*News*

*No new digest content identified.*

**EDCTP** [to 21 Sep 2024]

<http://www.edctp.org/>

*The European & Developing Countries Clinical Trials Partnership (EDCTP) aims to accelerate the development of new or improved drugs, vaccines, microbicides and diagnostics against HIV/AIDS, tuberculosis and malaria as well as other poverty-related and neglected infectious diseases in sub-Saharan Africa, with a focus on phase II and III clinical trials*

*News*

*No new digest content identified.*

**Emory Vaccine Center** [to 21 Sep 2024]

<http://www.vaccines.emory.edu/>

*Vaccine Center News*

*No new digest content identified.*

**European Vaccine Initiative** [to 21 Sep 2024]

<http://www.euvaccine.eu/>

*Latest News, Events*

*No new digest content identified.*

**Evidence Aid** [to 21 Sep 2024]

*Evidence Aid aims to save lives and livelihoods in disasters by providing decision-makers with the best available evidence and by championing its use.*

<http://www.evidenceaid.org/>

*Resources [Selected]*

*No new digest content identified.*

**Fondation Merieux** [to 21 Sep 2024]

<http://www.fondation-merieux.org/>

*News, Events*

*No new digest content identified.*

**Gavi** [to 21 Sep 2024]

<https://www.gavi.org/>

*Press Releases*

18 September 2024

### **Gavi Signs Agreement with Bavarian Nordic to Rapidly Secure 500,000 Doses of Mpox Vaccines for Africa**

:: The advance purchase agreement (APA) will be funded by Gavi's First Response Fund, a mechanism created after the COVID-19 pandemic to ensure rapid access to scarce vaccine supplies in future health emergencies.

:: Availability of all 500,000 doses has been secured for 2024.

COPENHAGEN, Denmark and GENEVA, Switzerland, September 18, 2024 – Bavarian Nordic A/S (OMX: BAVA) and Gavi, the Vaccine Alliance today announced an advance purchase agreement (APA) to secure 500,000 doses of the MVA-BN® mpox vaccine (marketed as JYNNEOS® or IMVANEX®) to be supplied to countries in Africa impacted by the mpox outbreak. The doses will be for delivery in



2024. The vaccines will be funded by Gavi's First Response Fund, a new financial mechanism created in June 2024 to make cash rapidly available to purchase vaccines in health emergencies...

**GE2P2 Global Foundation** [to 21 Sep 2024]

[www.ge2p2.org](http://www.ge2p2.org)

*News/Analysis/Publications-Digests/Statements*

:: [Vaccines and Global Health: The Week in Review](#) - Current edition

:: [Informed Consent: A Monthly Review – June 2024](#)

:: [Public Consultations Watch :: Global Calls for Input/Public Comment – 10 Sep 2024 – Issue 23](#)

**GHIT Fund** [to 21 Sep 2024]

<https://www.ghitfund.org/newsroom/press>

*Press Releases*

September 17, 2024

[\*\*Dr. Quarraisha Abdool Karim, Hideyo Noguchi Africa Prize Winner, Joins GHIT Fund Board of Directors\*\*](#)

**Global Fund** [to 21 Sep 2024]

<https://www.theglobalfund.org/en/news/>

19 September 2024

[\*\*Global Fund Report Highlights Major Strides Against HIV, TB and Malaria, Lowered Prices for Essential Medicines\*\*](#)

Investments in the fight against HIV, tuberculosis (TB) and malaria have saved a total of 65 million lives and cut the combined death rate from the three diseases by 61% since 2002, according to a new report by the Global Fund to Fight AIDS, Tubercul...

18 September 2024

[\*\*Global Fund Provides Nearly US\\$10 Million for DRC's Mpox Response\*\*](#)

At the request of the government of the Democratic Republic of the Congo (DRC), the Global Fund to Fight AIDS, Tuberculosis and Malaria (the Global Fund) is supporting the country with US\$9.5 million for its emergency mpox response in six of the high...

**Global Research Collaboration for Infectious Disease Preparedness [GloPID-R]** [to 21 Sep 2024]

<https://www.glopid-r.org/news/>

*News*

*No new digest content identified.*

**Hilleman Laboratories** [to 21 Sep 2024]

<http://www.hilleman-labs.org/>

*News & Insights*

*No new digest content identified.*

**HHMI - Howard Hughes Medical Institute** [to 21 Sep 2024]

<https://www.hhmi.org/news>

*Press Room*

*No new digest content identified.*

**Human Immunome Project [nee Human Vaccines Project]** [to 21 Sep 2024]

<https://www.humanimmunomeproject.org/>

*News*

*No new digest content identified.*

**IAVI** [to 21 Sep 2024]

<https://www.iavi.org/>

*News, Features*

*No new digest content identified.*

**INSERM** [to 21 Sep 2024]

<https://www.inserm.fr/en/home/>

*Press Releases*

*No new digest content identified.*

**International Coalition of Medicines Regulatory Authorities [ICMRA]**

<http://www.icmra.info/drupal/en/news>

*Selected Statements, Press Releases, Research*

*No new digest content identified.*

**ICH [International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use]** [to 21 Sep 2024]

<https://www.ich.org/>

*News/Pubs/Press Releases [Selective]*

*No new digest content identified.*

**ICRC** [to 21 Sep 2024]

<https://www.icrc.org/en/whats-new>

*What's New [Selected]*

*News Release*

**[West Africa: Red Cross teams increase humanitarian assistance after floods hit conflict areas](#)**

20-09-2024

**IFFIm**

<http://www.iffim.org/>

*Press Releases/Announcements*

**[Armed with vaccine, families in Benin take the fight to malaria](#)**

17 Sep 2024

215,900 doses of malaria vaccine began to roll out in Benin in April – and they've been welcomed with open arms, finds reporter Edna Fleure.

**IFRC** [to 21 Sep 2024]

<http://media.ifrc.org/ifrc/news/press-releases/>

*Press Releases [Selected]*

*Press release 19/09/2024*

**Devastating floods displace huge swathes of the population across West and Central Africa**

*Press release 17/09/2024*

**Super Typhoon Yagi causes severe flooding across Southeast Asia**

*Press release 16/09/2024*

**Red Cross teams respond to 'historic' floods across Central Europe**

.

**Institut Pasteur** [to 21 Sep 2024]

<https://www.pasteur.fr/en/press-area>

*Press Documents*

*No new digest content identified.*

**ISC / International Science Council** [to 21 Sep 2024]

<https://council.science/current/>

*Latest Updates*

*statement*

**Statement of the UNSG's Scientific Advisory Board on Trust in Science**

*September 17, 2024*

*blog*

*19 September 2024 - 10 min read*

**ISC Fellows Letter to the scientific community on the occasion of the Summit of the Future**

**International Union of Immunological Societies (IUIS)**

<https://iuis.org/>

*News/Events [Selected]*

*No new digest content identified.*

**IVAC** [to 21 Sep 2024]

<https://www.jhsph.edu/research/centers-and-institutes/ivac/index.html>

*Updates; Events*

*No new digest content identified.*

**IVI** [to 21 Sep 2024]

<http://www.ivi.int/>

*IVI News & Announcements*

*No new digest content identified.*

**Johns Hopkins Center for Health Security** [to 21 Sep 2024]

<https://centerforhealthsecurity.org/newsroom>

*Center News [Selected]*  
*No new digest content identified.*

**MSF/Médecins Sans Frontières** [to 21 Sep 2024]

<http://www.msf.org/>

*Latest [Selected Announcements]*

*Nigeria*

**Fears of outbreaks grow in Maiduguri following severe flooding**

Press Release 20 Sep 2024

**National Academy of Medicine** - USA [to 21 Sep 2024]

<https://nam.edu/programs/>

*News [Selected]*

**Three NAM Members Receive 2024 Lasker Awards**

September 19, 2024

The Lasker Foundation has announced the winners of its 2024 Lasker Awards in biomedical research, with three National Academy of Medicine (NAM) members among the awardees.

**Zhijian (James) Chen** was honored with the Albert Lasker Basic Medical Research Award for “the discovery of the cGAS enzyme that senses foreign and self DNA, solving the mystery of how DNA stimulates immune and inflammatory responses.” Chen was elected to the NAM in 2022 and to the National Academy of Sciences in 2014.

**Quarraisha Abdool Karim** and **Salim S. Abdool Karim** were honored with the Lasker~Bloomberg Public Service Award for “for illuminating key drivers of heterosexual HIV transmission; introducing life-saving approaches to prevent and treat HIV; and statesmanship in public health policy and advocacy.” Quarraisha Abdool Karim was elected to the NAM in 2014, and Salim S. Abdool Karim was elected to the NAM in 2012.

**National Academies-Sciences-Engineering-Medicine [NASEM]**- USA [to 21 Sep 2024]

<https://www.nationalacademies.org/newsroom?>

*News*

**National Academies Add Philanthropists to Their Long-Standing Brain Trust of Government, University, and Industry Leaders**

News Release | September 18, 2024

WASHINGTON — The National Academies of Sciences, Engineering, and Medicine’s Government-University-Industry Research Roundtable (GUIRR) — a forum for leaders to discuss the U.S. scientific research enterprise — has announced the inclusion of philanthropy leadership in the long-standing group. The roundtable’s new name is the Government-University-Industry-Philanthropy Research Roundtable (GUIPRR)...

**National Vaccine Program Office** - U.S. HHS [to 21 Sep 2024]

<https://www.hhs.gov/vaccines/about/index.html>

*Upcoming Meetings/Latest Updates*

*No new digest content identified.*

**NIH** [to 21 Sep 2024]

<http://www.nih.gov/>

Tuesday, September 17, 2024

**NIH releases mpox research agenda**

*Plan will advance knowledge of virus biology to improve detection, treatment and prevention.*

<http://www.nih.gov/>

**PATH** [to 21 Sep 2024]

<https://www.path.org/media-center/>

*Newsroom*

**WA State Department of Health and PATH join forces to leverage global health best practices in Washington State**

*New efforts to harness global learnings into statewide strategies bring exciting possibilities for public health in Washington State.*

**Sabin Vaccine Institute** [to 21 Sep 2024]

<https://www.sabin.org/press/>

*Latest News & Press Releases*

*No new digest content identified.*

**UNAIDS** [to 21 Sep 2024]

<http://www.unaids.org/en>

*News, Stories, Updates*

**At UNGA79 UNAIDS will call on global leaders to roll-out new, breakthrough medicines which are nearly 100% effective in preventing HIV and show that at this moment of global crisis the AIDS response proves what's possible when leaders work boldly together**

19 September 2024

**UNICEF** [to 21 Sep 2024]

<https://www.unicef.org/media/press-releases>

*Latest press releases, news notes and statements*

*Remarks*

20 September 2024

**Children Hit Hard by Mpox**

BUJUMBURA/GENEVA, 20 SEPTEMBER 2024 –“Children in Burundi are bearing the brunt of the mpox outbreak, with alarming rates of infection and severe health impacts. Of the nearly 600 reported cases, two-thirds are in children under 19. The situation has escalated rapidly, with a more than 40% increase in cases ...

*Remarks* 19 September 2024

**UNICEF Deputy Executive Director Ted Chaiban media briefing on mission to Israel, the Gaza Strip and the West Bank**

NEW YORK/Jordan, 19 September 2024 - “I know we are all concerned with the situation involving Lebanon and Israel and the Secretary-General has urged all concerned to exercise maximum restraint to avert any further escalation and any further escalation would be terrible in terms of consequences for children. “Toda...

*Press release* 17 September 2024

**One-third of mpox cases in Burundi among school-age children – UNICEF**

BUJUMBURA, 17 September 2024 – School-age children between 5 and 19 years old now account for 33 per cent of mpox cases in Burundi, presenting a new challenge as families prepare for the upcoming school year. “The rising number of mpox cases among children in Burundi, including children under five, is deeply conce...

*News note* 16 September 2024

**[UNICEF appeals for US\\$58.8 million to address mpox crisis as cases among children rise](#)**

NEW YORK, 16 September 2024 – UNICEF has launched an appeal for US\$58.8 million to address the rising mpox crisis across six African countries where children are most affected. Though child deaths are currently confined to the Democratic Republic of the Congo (DRC), the data underscores their vulnerability, as UNI...

**Unitaid** [to 21 Sep 2024]

<https://unitaid.org/>

*Featured News*

18 September 2024

**[Unitaid unveils new report on technologies to prevent cervical cancer, a leading killer of women worldwide](#)**

*Key points*

:: Unitaid’s latest technology landscape report, launched today at the World Cancer Congress in Geneva, is a comprehensive repository of existing technologies – and promising new tools on the horizon – for screening, detection, and treatment of cervical precancerous lesions.

:: Approximately 350,000 women die from cervical cancer a year. About 94% of those deaths occur in low- and middle-income countries, where screening and treatment rates are low.

:: Cervical cancer can be cured if diagnosed at an early stage and treated promptly, but until recently, many of the available tools to detect and treat cervical cancer were unaffordable or ill-suited for low-resource settings.

:: Coupled with vaccination efforts, cervical cancer can be eliminated within our lifetime if programs adopt these screening and treatment technologies as part of comprehensive prevention strategies and at scale.

**Vaccine Equity Cooperative [nee Initiative]** [to 21 Sep 2024]

<https://vaccineequitycooperative.org/news/>

*News*

*No new digest content identified.*

**Vaccination Acceptance & Demand Initiative [Sabin]** [to 21 Sep 2024]

<https://www.vaccineacceptance.org/>

*Announcements, Blog*

*No new digest content identified.*

**Vaccine Confidence Project** [to 21 Sep 2024]

<http://www.vaccineconfidence.org/>

*News, Research and Reports*

*No new digest content identified.*

**Vaccine Education Center – Children’s Hospital of Philadelphia** [to 21 Sep 2024]

<http://www.chop.edu/centers-programs/vaccine-education-center>

*News*

*No new digest content identified.*

**Wellcome Trust** [to 21 Sep 2024]

<https://wellcome.org/news/all>

*News, Opinion, Reports*

*No new digest content identified.*

**The Wistar Institute** [to 21 Sep 2024]

<https://www.wistar.org/news/press-releases>

*Press Releases*

September 17, 2024

**[Wistar Institute Researchers Identify Parkinson-related Protein's Role in Cancer and T Cell Activation](#)**

Wistar's Altieri lab uncovered the protein's powerful influence on immune response to tumors

September 16, 2024

**[Scientists at The Wistar Institute Clone Several New Anti-Interferon Antibodies, Developing Future Therapeutic Candidates with Broad Application Potential](#)**

Honored as the Top Read in the September 15 Issue of the Journal of Immunology

**World Bank** [to 21 Sep 2024]

<http://www.worldbank.org/en/news/all>

*All News [Selected]*

**[World Bank's New Framework to Boost Sustainable and Inclusive Artisanal and Small-Scale Mining](#)**

WASHINGTON, Sep. 19, 2024—The World Bank today unveiled a bold new vision to unlock the full potential of Artisanal and small-scale mining (ASM) to drive economic growth, boost development, and reduce...

Date: September 19, 2024 Type: Press Release

**WFPHA: World Federation of Public Health Associations** [to 21 Sep 2024]

<https://www.wfpha.org/>

*Blog, Events*

*No new digest announcements identified.*

**World Medical Association [WMA]** [to 21 Sep 2024]

<https://www.wma.net/news-press/press-releases/>

*Press Releases*

**[WMA calls for governments' cooperation in mpox public health emergency](#)**

19.08.2024

**[On World Humanitarian Day, health professionals call for protection in conflicts](#)**

19.08.2024



**World Organisation for Animal Health [OIE]** [to 21 Sep 2024]

<https://www.oie.int/>

*Press Releases, Statements*

*Website not responding at inquiry.*

.....

.....

**ARM [Alliance for Regenerative Medicine]** [to 21 Sep 2024]

<https://alliancerm.org/press-releases/>

*Selected Press Releases*

*No new digest content identified.*

**BIO** [to 21 Sep 2024]

<https://www.bio.org/press-releases>

*Press Releases*

*No new digest announcements identified.*

**DCVMN – Developing Country Vaccine Manufacturers Network** [to 21 Sep 2024]

<http://www.dcvmn.org/>

*News; Upcoming events*

**ANNUAL GENERAL MEETING 2024**

October 16 - 18, 2024 São Paulo, Brazil

**ICBA – International Council of Biotechnology Associations** [to 21 Sep 2024]

<https://internationalbiotech.org/news/>

*News*

*No new digest announcements identified.*

**IFPMA** [to 21 Sep 2024]

<https://ifpma.org/>

*News, Statements [Selected]*

*Statement 16 September 2024*

**Innovative pharmaceutical industry leaders reinforce ethics and business integrity in APEC economies and health sectors**

IFPMA, with support and representation from industry leaders, joins stakeholders this week at the 11th Business Ethics for APEC SMEs Forum. This Forum – and the initiative on which it is based – supports the advancement of ethical business practices in the Asia-Pacific economies, with a focus on the health sector and wider health ecosystem. IFPMA and companies have engaged in the Initiative across its diverse priorities and activities, all of which are designed to drive a level playing field in key markets and a sustainable healthcare ecosystem.

APEC includes several of the world's largest and / or fastest growing pharmaceutical production, consumption, and R&D markets, including United States, Japan, China, Canada, Korea, Mexico, and Australia. The Business Ethics for SMEs Initiative brings together the medical devices and pharmaceutical sectors to advance principles on ethics and integrity. This includes through the development of the Mexico City Principles, which stipulate sector-wide ethical guidance to meet the highest standards for patients, as well as consensus frameworks, research, and government

engagement. This collective action has made a tangible impact on nearly 20,000 enterprises of every size across the APEC region.

As the leading industry partner for the biopharmaceutical sector, IFPMA and our members are proud to participate in the Business Ethics for APEC SMEs Initiative and share what it signifies for ethics and business integrity worldwide.

### **International Alliance of Patients' Organizations – IAPO** [to 21 Sep 2024]

<https://www.iapo.org.uk/news>

*Press and media [Selected]*

*No new digest announcements identified.*

### **International Generic and Biosimilar Medicines Association [IGBA]**

<https://www.igbamedicines.org/>

*News*

#### **AMIP, the Moroccan Pharmaceutical Industry Association, joins IGBA (September 2024)**

IGBA, the International Generic and Biosimilar medicines Association, representing global manufacturers of generic and biosimilar medicines, announced today that AMIP has been accepted and welcomed as a new IGBA Associate Member.

### **PhRMA** [to 21 Sep 2024]

<http://www.phrma.org/>

*Press Releases*

*No new digest announcements identified.*

.....  
.....

### ***Vaccines/Therapeutics/Medicines – Selected Developer/Manufacturer Announcements***

#### **AstraZeneca**

*Press Releases*

#### **FluMist approved for self-administration in the US**

Only influenza vaccine approved for self- or caregiver-administration at home, expanding options for influenza protection

20 September 2024

FluMist has been approved in the US as the only self-administered influenza vaccine. FluMist, a needle-free nasal spray, was approved to be self-administered by adults up to 49 years of age or administered by a parent/caregiver to individuals 2-17 years of age.<sup>1</sup>

The approval by the US Food and Drug Administration (FDA) was based on a comprehensive submission, which included results from a usability study demonstrating that individuals over 18 years of age could self-administer or administer FluMist to eligible individuals 2-49 years of age.<sup>1</sup>...

#### **Bavarian Nordic**

*Latest News*

September 19, 2024

#### **Bavarian Nordic Receives EMA Approval of Mpox Vaccine for Adolescents**

:: MVA-BN approved for use against mpox and smallpox in adolescents 12-17 years of age after expedited review with EMA

:: Represents the second EMA approval of an MVA-BN-based vaccine for a younger population

COPENHAGEN, Denmark, September 19, 2024 – Bavarian Nordic A/S (OMX: BAVA) announced today that the European Commission has adopted the Committee for Medicinal Products for Human Use (CHMP) recommendation for the approval of a type II variation for IMVANEX® (MVA-BN) smallpox and mpox vaccine, extending the current marketing authorization to include adolescents 12 to 17 years of age...

September 18, 2024

**[Gavi Signs Agreement with Bavarian Nordic to Rapidly Secure 500,000 Doses of Mpox Vaccines for Africa](#)**

:: The advance purchase agreement (APA) will be funded by Gavi's First Response Fund, a mechanism created after the COVID-19 pandemic to ensure rapid access to scarce vaccine supplies in future health emergencies.

:: Availability of all 500,000 doses has been secured for 2024.

COPENHAGEN, Denmark and GENEVA, Switzerland, September 18, 2024 – Bavarian Nordic A/S (OMX: BAVA) and Gavi, the Vaccine Alliance today announced an advance purchase agreement (APA) to secure 500,000 doses of the MVA-BN® mpox vaccine (marketed as JYNNEOS® or IMVANEX®) to be supplied to countries in Africa impacted by the mpox outbreak. The doses will be for delivery in 2024.

The vaccines will be funded by Gavi's First Response Fund, a new financial mechanism created in June 2024 to make cash rapidly available to purchase vaccines in health emergencies...

**Bharat Biotech**

Press Releases - No new digest announcements identified

**BioCubaFarma** – Cuba

Últimas Noticias - No new digest announcements identified

**Biological E**

News - No new digest announcements identified

**BioNTech**

Press Releases

20 September 2024

**[Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron KP.2-adapted COVID-19 Vaccine in the European Union](#)**

**Boehringer**

Press Releases - No new digest announcements identified

**CanSinoBIO**

News - Website not responding at inquiry

**CIGB**

Latest News - No new digest announcements identified.

**Cinnagen**

Recent News - No new digest announcements identified.

**Clover Biopharmaceuticals** – China

News - No new digest announcements identified.

**Curevac**

News - No new digest announcements identified.

### **Gamaleya National Center/Sputnik**

Latest News and Events - No new digest announcements identified [Last: 09 Nov 2020]  
<https://sputnikvaccine.com/> - No new digest announcements identified [Last: 31 Aug 2022]

### **GSK**

Press releases for media - No new digest announcements identified.

### **EuBiologics, S Korea**

News - No new digest announcements identified.

### **IMBCAMS, China**

Home - Website not responding at inquiry.

### **Janssen/JNJ**

Press Releases - No new digest announcements identified.

### **Merck**

News releases - No new digest announcements identified.

### **Moderna**

Press Releases

September 17, 2024

[Moderna Receives Health Canada Approval For Updated COVID-19 Vaccine Targeting KP.2 Variant Of SARS-COV-2 For Ages Six Months And Older](#)

### **Nanogen**

News - No new digest announcements identified

### **Novartis**

News - No new digest announcements identified.

### **Novavax**

Press Releases - No new digest announcements identified.

### **Pfizer**

Recent Press Releases -

09.20.2024

[Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron KP.2-adapted COVID-19 Vaccine in the European Union](#)

### **R-Pharm**

<https://rpharm-us.com/index.php>

[No news or media page identified]

### **Sanofi Pasteur**

Press Releases - No new digest announcements identified

### **Serum Institute of India**

NEWS & ANNOUNCEMENTS - No new digest announcements identified

## **Sinopharm/WIBPBIBP**

News - No new digest announcements identified

## **Sinovac**

Press Releases - No new digest announcements identified.

## **SK Biosciences**

Press Releases - No new digest announcements identified.

## **Takeda**

Newsroom

**Takeda Commits Over \$32 Million in Five New Global Corporate Social Responsibility Partnerships To Further Drive Health Impact in 93 Countries**

September 18, 2024

## **Valneva**

Press Releases

September 18, 2024

**Valneva Submits Label Extension Applications for its Chikungunya Vaccine, IXCHIQ®, to EMA and Health Canada**

*To potentially include adolescents and antibody persistence up to two years*

## **Vector State Research Centre of Virology and Biotechnology**

Home - [Website not responding [404 error]]

## **WestVac Biopharma**

Media - No new digest announcements identified.

## **Zhifei Longcom, China**

[Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.]

Website [No News/Announcements page identified]

.....  
.....

### ***Contents [click to move among sections]***

:: Milestones, Perspectives

:: WHO

:: Organization Announcements

:: Journal Watch

:: Pre-Print Servers

.....  
.....

## ***Journal Watch***

*Vaccines and Global Health: The Week in Review* continues its weekly scanning of key peer-reviewed journals to identify and cite articles, commentary and editorials, books reviews and other content supporting our focus on vaccine ethics and policy. Journal Watch is not intended to be exhaustive, but indicative of themes and issues the Center is actively tracking. We selectively provide full text of some editorial and comment articles that are specifically relevant to our work. Successful access to some of the links provided may require subscription or other access arrangement unique to the publisher.

If you would like to suggest other journal titles to include in this service, please contact David Curry at: [david.r.curry@centerforvaccineethicsandpolicy.org](mailto:david.r.curry@centerforvaccineethicsandpolicy.org)

### **AJOB Empirical Bioethics**

Volume 15, 2023 Issue 3

<https://www.tandfonline.com/toc/uabr21/current>

[Reviewed earlier]

### **AMA Journal of Ethics**

Volume 26, Number 9: E665-744

<https://journalofethics.ama-assn.org/issue/nonhuman-animal-research>

#### ***Nonhuman Animal Research***

Nonhuman animals have long been and continue to be routinely used in biomedical and behavioral research to promote human health. When SARS-CoV2 infections triggered a race to develop and scale global access to vaccines in 2019, two key innovations happened to the supply chain of nonhuman animals created, raised, and used for science: (1) experiments and trials regarded as essential were prioritized and (2) governments and researchers shortened vaccine production timelines. Clinical and public health urgency concentrated and acutely focused demand for live mammals—especially ferrets, guinea pigs, hamsters, mice, nonhuman primates, pigs, and rats—in ways that also intensified demand for efficient protocol designs and streamlined methods of human vaccine research and development. Reasonable people can still disagree about when, why, and how nonhuman animals should be sacrificed for human health, but we now know that human health endeavors, specifically vaccine development, flourish even when we sanction fewer nonhuman animals' cultivation and deaths for science. This theme issue investigates what this revelation from the pandemic means from clinical, ethical, legal, and policy standpoints for the future of human-centered research.

### **American Journal of Human Genetics**

Sep 05, 2024 Volume 111 Issue 9 p1797-2070

<https://www.cell.com/ajhg/current>

#### ***This Month in The Journal***

Alyson B. Barnes, Kylee L. Spencer

Proteogenomics draws on the fields of genomics, transcriptomics, and proteomics to discern how genetic variation influences the set of proteins produced by a cell with the goal of elucidating how this relates to disease risk. Although colocalization approaches can be used to identify variants that are tied to both splicing and disease, the limitations of short-read RNA sequencing have often prevented determining which protein isoform or group of isoforms specifically mediates risk. In this issue, Abood et al.

*Review* Online now September 18, 2024

#### **International policies guiding the selection, analysis, and clinical management of secondary findings from genomic sequencing: A systematic review**

Safa Majeed<sup>1,2</sup> · Christine Johnston<sup>1</sup> · Saumeh Saeedi<sup>4</sup> · ... · Ashby Kissoondoyal<sup>2</sup> · David Malkin<sup>1,2,5,6</sup> · Yvonne Bombard<sup>3,4,7</sup> [yvonne.bombard@utoronto.ca](mailto:yvonne.bombard@utoronto.ca) [[yvonne.bombard@utoronto.ca](mailto:yvonne.bombard@utoronto.ca)]...

#### ***Summary***

Secondary findings (SFs) from genomic sequencing can have significant impacts on patient health, yet existing practices guiding their clinical investigation are inconsistent. We systematically reviewed existing SFs policies to identify variations and gaps in guidance. We cataloged and appraised international policies from academic databases ( $n = 5$ ; inception-02/2022) and international human genetic societies ( $n = 64$ ; inception-05/2022), across the continuum of SFs selection, analysis, and

clinical management. We assessed quality using AGREE-II and interpreted results using qualitative description. Of the 63 SFs policies identified, most pertained to clinical management of SFs (98%;  $n = 62$ ; primarily consent and disclosure), some guided SFs analysis (60%;  $n = 38$ ), while fewer mentioned SFs selection (48%;  $n = 30$ ). Overall, policies recommend (1) identifying clinically actionable, pathogenic variants with high positive predictive values for disease (selection), (2) bioinformatically filtering variants using evidence-informed gene lists (analysis), and (3) discussing with affected individuals the SFs identified, their penetrance, expressivity, medical implications, and management (clinical management). Best practices for SFs variant analysis, clinical validation, and follow-up (i.e., surveillance, treatment, etc.) were minimally described. Upon quality assessment, policies were highly rated for scope and clarity (median score, 69) but were limited by their rigor and applicability (median scores, 27 and 25). Our review represents a comprehensive international synthesis of policy guiding SFs across the continuum of selection, analysis, and clinical management. Our synthesis will help providers navigate critical decision points in SFs investigation, although significant work is needed to address gaps in SFs analysis, clinical validation, and follow-up processes and to support evidence-based practice.

### **American Journal of Infection Control**

September 2024 Volume 52 Issue 9 p985-1104

<http://www.ajicjournal.org/current>

[Reviewed earlier]

### **American Journal of Preventive Medicine**

September 2024 Volume 67 Issue 3 p319-476

<https://www.ajpmonline.org/current>

[Reviewed earlier]

### **American Journal of Public Health**

October 2024 114(109)

<http://ajph.aphapublications.org/toc/ajph/current>

[Reviewed earlier]

### **American Journal of Tropical Medicine and Hygiene**

Volume 111 (2024): Issue 3 (Sep 2024)

<https://www.ajtmh.org/view/journals/tpmd/111/3/tpmd.111.issue-3.xml>

[Reviewed earlier]

### **Annals of Internal Medicine**

September 2024 Volume 177, Issue 9

<https://www.acpjournals.org/toc/aim/current>

*Position Papers*

**[Ethics and Academic Discourse, Scientific Integrity, Uncertainty, and Disinformation in Medicine: An American College of Physicians Position Paper](#)**

Lois Snyder Sulmasy, JD, Joel R. Burnett, MD, Jan K. Carney, MD, MPH, and [... et al.](#)

Pages:1244–1250

*Editorials*

**[Long COVID Diagnostics: An Unconquered Challenge](#)**



Annukka A.R. Antar, MD, PhD, Paul G. Auwaerter, MD  
Pages:1279–1280

## **Artificial Intelligence – An International Journal**

Volume 334 September 2024

<https://www.sciencedirect.com/journal/artificial-intelligence/vol/334/suppl/C>

[Reviewed earlier]

## **BMC Cost Effectiveness and Resource Allocation**

<http://resource-allocation.biomedcentral.com/>

(Accessed 21 Sep 2024)

### **[Global bibliometric analysis of cost effectiveness analysis in healthcare research from 2013 to 2023](#)**

*Cost-effectiveness analysis (CEA) has become a crucial technique in appraising the efficiency of healthcare interventions and resource allocation decisions. Cost-effectiveness analysis is now widely used to evaluate whether the effect of a healthcare intervention justifies additional expenditure.*

Authors: Kemdi Lugard Okoroiwu, Henshaw Uchechi Okoroiwu, Love Ogochukwu Ude, Chidimma Odilia Ezuma and Emmanuel Ikechukwu Omeje

Citation: *Cost Effectiveness and Resource Allocation* 2024 22:68

Content type: Research Published on: 16 September 2024

## **BMC Health Services Research**

<http://www.biomedcentral.com/bmchealthservres/content>

(Accessed 21 Sep 2024)

[No new digest content identified]

## **BMC Infectious Diseases**

<http://www.biomedcentral.com/bmcinfectdis/content>

(Accessed 21 Sep 2024)

### **[COVID-19 breakthrough infections in vaccinated individuals at BPKIHS, Nepal](#)**

*Although there have been reports of COVID-19 breakthrough infections in vaccinated individuals, the vaccines have demonstrated a high efficacy in preventing severe illness and death. Nepal has reported fewer s...*

Authors: Abhishek Karmacharya, Keshav Rai, Shraddha Siwakoti, Basudha Khanal and Narayan Raj Bhattarai

Citation: *BMC Infectious Diseases* 2024 24:1003

Content type: Research Published on: 19 September 2024

### **[Effectiveness of inactivated COVID-19 vaccines in preventing COVID-19-related hospitalization during the Omicron BF.7-predominant epidemic wave in Beijing, China: a cohort study](#)**

*To estimate vaccine effectiveness(VE) against COVID-19-related hospitalization for inactivated vaccines during the Omicron BF.7-predominant epidemic wave in Beijing, China.*

Authors: Dan Zhao, Ying Sun, Juan Li, Xiaomei LI, Ying Ma, Zhiqiang Cao, Jiaojiao Zhang, Jiaxin Ma, Jia Li, Quanyi Wang, Luodan Suo, Daitao Zhang and Peng Yang

Citation: *BMC Infectious Diseases* 2024 24:991

Content type: Research Published on: 17 September 2024

## **Surveillance of adverse events following varicella vaccine immunization in Jiangsu province, China from 2017 to 2023**

*To assess the safety of varicella vaccine (VarV) by conducting post-marketing surveillance on adverse events following immunization (AEFI) in Jiangsu Province, China.*

Authors: Lei Zhang, YaLi Fu, Wen Wang, YuanBao Liu, Ran Hu, Zhiguo Wang and Xiang Sun

Citation: *BMC Infectious Diseases* 2024 24:983

Content type: Research Published on: 16 September 2024

### **BMC Medical Ethics**

<http://www.biomedcentral.com/bmcmedethics/content>

(Accessed 21 Sep 2024)

[No new digest content identified]

### **BMC Medicine**

<http://www.biomedcentral.com/bmcmed/content>

(Accessed 21 Sep 2024)

[No new digest content identified]

### **BMC Pregnancy and Childbirth**

<http://www.biomedcentral.com/bmcpregnancychildbirth/content>

(Accessed 21 Sep 2024)

[No new digest content identified]

### **BMC Public Health**

<http://bmcpublichealth.biomedcentral.com/articles>

(Accessed 21 Sep 2024)

#### **COVID-19 vaccine uptake in individuals with functional difficulty, disability, and comorbid conditions: insights from a national survey in Bangladesh**

*COVID-19 vaccine uptake among individuals with disabilities is crucial for safeguarding their health and well-being. However, the extent of vaccine uptake among this group remains largely unknown in low- and m...*

Authors: Shimlin Jahan Khanam, Md. Shohel Rana, M. Mofizul Islam and Md. Nuruzzaman Khan

Citation: *BMC Public Health* 2024 24:2531

Content type: Research Published on: 17 September 2024

### **BMC Research Notes**

<http://www.biomedcentral.com/bmcresnotes/content>

(Accessed 21 Sep 2024)

[No new digest content identified]

### **BMJ Evidence-Based Medicine**

October 2024 - Volume 29 - 5

<https://ebm.bmj.com/content/29/5>

*Education*

#### **Global considerations for informed consent with shared decision-making in the digital age**

(2 May, 2024)

Edward Robert St John, Connor James Stewart Moore, Raghu Ram Pillarisetti, Erica Sarah Spatz

### *Background*

Shared decision-making (SDM) is increasingly recognised as fundamental to patient-centred care and enabling patients to make voluntary, informed decisions about their health.<sup>1</sup> SDM is the process whereby patients and clinicians come together to share their expertise. The patient acts as an expert of themselves, understanding their own preferences and their attitudes to risk. The clinician is an expert on the medical knowledge and scientific evidence. Together, treatment options should be explored, arriving at a treatment decision that is right for the patient and supported by the clinician. When dealing with invasive or high-risk procedures (eg, operations, chemotherapy, radiotherapy, immunotherapy), once the treatment decision has been made, the conversation turns to informed consent. This is the process of communicating and agreeing to the potential risks and benefits of the procedure, while acknowledging that there are alternative treatment options that have not been chosen. Though informed consent should be the culmination of SDM, alone it does not encapsulate the entire process. There is a distinction between decision-making and consent and this should ideally be accompanied by a period for reflection. Despite advances in SDM, the subsequent informed consent process has remained stagnant, often failing to meet ethical or legal standards of supporting meaningful patient autonomy.<sup>2</sup> ...

### **BMJ Global Health**

September 2024 - Volume 9 - 9

<https://gh.bmj.com/content/9/9>

[Reviewed earlier]

### **Bulletin of the Atomic Scientists**

September 2024

<https://thebulletin.org/magazine/2024-09/>

[Reviewed earlier]

### **Bulletin of the World Health Organization**

Volume 102(9); 2024 Sep 1

<https://www.ncbi.nlm.nih.gov/pmc/issues/469680/>

[Reviewed earlier]

### **Cell**

Sep 05, 2024 Volume 187 Issue 18 p4813-5118

<https://www.cell.com/cell/current>

[Reviewed earlier]

### **Child Care, Health and Development**

Volume 50, Issue 5 September 2024

<https://onlinelibrary.wiley.com/toc/13652214/current>

[Reviewed earlier]

### **Clinical Pharmacology & Therapeutics**

Volume 116, Issue 3 Pages: 479-874 September 2024

<https://ascpt.onlinelibrary.wiley.com/toc/15326535/current>

### ***Issue Focus: Getting the Dosage Right***

[Reviewed earlier]

### **Clinical Therapeutics**

September 2024 Volume 46 Issue 9 p661-726

<http://www.clinicaltherapeutics.com/current>

[Reviewed earlier]

### **Clinical Trials**

Volume 21 Issue 4, August 2024

<https://journals.sagepub.com/toc/ctja/21/4>

[Reviewed earlier]

### **Conflict and Health**

<http://www.conflictandhealth.com/>

[Accessed 21 Sep 2024]

[No new digest content identified]

### **Contemporary Clinical Trials**

Volume 144 September 2024

<https://www.sciencedirect.com/journal/contemporary-clinical-trials/vol/144/suppl/C>

[Reviewed earlier]

### **The CRISPR Journal**

Volume 7, Issue 4 / August 2024

<https://www.liebertpub.com/toc/crispr/7/4>

[Reviewed earlier]

### **Current Genetic Medicine Reports**

Volume 11, Issue 3-4 December 2023

<https://link.springer.com/journal/40142/volumes-and-issues/11-3>

[Reviewed earlier]

### **Current Medical Research and Opinion**

Volume 40, Issue 8 2024

<https://www.tandfonline.com/toc/icmo20/current>

[Reviewed earlier]

### **Current Opinion in Infectious Diseases**

October 2024 - Volume 37 - Issue 5

<https://journals.lww.com/co-infectiousdiseases/pages/currenttoc.aspx>

*TROPICAL AND TRAVEL-ASSOCIATED DISEASES*

**[Immune responses and severe dengue: what have we learned?](#)**

Malavige, Gathsaurie Neelika; Ogg, Graham S.

Current Opinion in Infectious Diseases. 37(5):349-356, October 2024.

### **Current Protocols in Human Genetics**

<https://currentprotocols.onlinelibrary.wiley.com/journal/19348258>

[Accessed 21 Sep 2024]

[No new digest content identified]

### **Developing World Bioethics**

Volume 24, Issue 3 Pages: 135-261 September 2024

<https://onlinelibrary.wiley.com/toc/14718847/current>

[Reviewed earlier]

### **Development in Practice**

Volume 34, Issue 6, 2024

<https://www.tandfonline.com/toc/cdip20/34/6>

[Reviewed earlier]

### **Development Policy Review**

Volume 42, Issue 5 September 2024

<https://onlinelibrary.wiley.com/toc/14677679/current>

[Reviewed earlier]

### **Disaster Medicine and Public Health Preparedness**

Volume 18 - 2024

<https://www.cambridge.org/core/journals/disaster-medicine-and-public-health-preparedness/latest-issue>

[Reviewed earlier]

### **Disasters**

Volume 48, Issue 3 July 2024

<https://onlinelibrary.wiley.com/toc/14677717/2024/48/3>

[Reviewed earlier]

### **EMBO Reports**

Volume 25 Issue 9 10 September 2024

<https://www.embopress.org/toc/14693178/current>

[Reviewed earlier]

### **Emerging Infectious Diseases**

Volume 30, Number 9—September 2024

<http://wwwnc.cdc.gov/eid/>

[Reviewed earlier]

## **Epidemics**

Volume 48 September 2024

<https://www.sciencedirect.com/journal/epidemics/vol/48/suppl/C>

[Reviewed earlier]

## **Epidemiology and Infection**

Volume 152 - 2024

<https://www.cambridge.org/core/journals/epidemiology-and-infection/latest-issue>

[Reviewed earlier]

## **Ethics & Human Research**

Volume 46, Issue 4 Pages: 1-51 July–August 2024

<https://onlinelibrary.wiley.com/toc/25782363/current>

***Research with refugee populations Ethical considerations for crowdsourced research***

[Reviewed earlier]

## **Ethics & International Affairs**

Volume 37 - Issue 4 - Winter 2023

<https://www.cambridge.org/core/journals/ethics-and-international-affairs/latest-issue>

[Reviewed earlier]

## **Ethics, Medicine and Public Health**

Volume 31 (December 2023)

<https://www.sciencedirect.com/journal/ethics-medicine-and-public-health/vol/31/suppl/C>

[Reviewed earlier]

## **The European Journal of Public Health**

Volume 34, Issue 4, August 2024

<https://academic.oup.com/eurpub/issue/34/4>

[Reviewed earlier]

## **Expert Review of Vaccines**

Vol 23 (1) 2023

<https://www.tandfonline.com/toc/ierv20/current>

[Reviewed earlier]

## **Foreign Affairs**

July/August 2024 Volume 103, Number 4

<https://www.foreignaffairs.com/issues/2023/103/4>

[Reviewed earlier]

## **Forum for Development Studies**

Volume 51, 2024 - Issue 2

<http://www.tandfonline.com/toc/sfds20/current>

[Reviewed earlier]

### **Genetics in Medicines**

Volume 26, Issue 9 September 2024

<https://www.sciencedirect.com/journal/genetics-in-medicine/vol/26/issue/9>

[Reviewed earlier]

### **Genome Medicine**

<https://genomemedicine.biomedcentral.com/articles>

[Accessed 21 Sep 2024]

[No new digest content identified]

### **Global Health Action**

Volume 17, Issue 1 (2024)

<https://www.tandfonline.com/toc/zgha20/current?nav=toCList>

[Reviewed earlier]

### **Global Health: Science and Practice (GHSP)**

Vol. 12, No. 4 August 27, 2024

<http://www.ghspjournal.org/content/current>

[Reviewed earlier]

### **Global Legal Monitor & Legal Reports – Library of Congress/USA**

<https://www.loc.gov/collections/global-legal-monitor/>

[https://www.loc.gov/books/?q=legal+reports&fa=partof%3Alegal+reports+%28publications+of+the+law+library+of+congress%29&sb=date\\_desc](https://www.loc.gov/books/?q=legal+reports&fa=partof%3Alegal+reports+%28publications+of+the+law+library+of+congress%29&sb=date_desc)

[Accessed 21 Sep 2024]

[No new digest content identified]

### **Global Public Health**

Volume 19, Issue 1 (2024)

<http://www.tandfonline.com/toc/rgph20/current>

[Reviewed earlier]

### **Globalization and Health**

<http://www.globalizationandhealth.com/>

[Accessed 21 Sep 2024]

[No new digest content identified]

### **Health and Human Rights**

Volume 26, Issue 1, June 2024

<https://www.hhrjournal.org/volume-26-issue-1-june-2024/>

***SPECIAL SECTION – COMMEMORATING 30 YEARS***



[Reviewed earlier]

### **Health Economics, Policy and Law**

Volume 19 - Issue 2 - April 2024

<https://www.cambridge.org/core/journals/health-economics-policy-and-law/latest-issue>

[Reviewed earlier]

### **Health Policy and Planning**

Volume 39, Issue 8, October 2024

<https://academic.oup.com/heapol/issue/39/8>

[Reviewed earlier]

### **Health Research Policy and Systems**

<http://www.health-policy-systems.com/content>

[Accessed 21 Sep 2024]

#### **[A transformative solution to build effective, transparent, and resilient “fit-for-purpose” national health research ethics systems](#)**

Authors: Manju Rani, Neha Chawla, Nitya Wadhwa, Roli Mathur, Timothy Jinks, Priyanka Das and Suman Rijal

Citation: *Health Research Policy and Systems* 2024 22:131

Content type: Review Published on: 20 September 2024

#### ***Abstract***

The current research ethics review systems are composed of isolated institutional Research Ethics Committees (RECs) that develop their own standard operating procedures (SOPs), templates and so on, with low adoption of digital solutions to manage submission and review processes. This poses several challenges, such as delays, higher costs, and hindering multi-site research. We propose an online national research ethics platform that all RECs can use, with common review processes and documentation requirements following national policy. The system will scale up adoption of digital solutions to all RECs. It will reduce administrative burden and harmonize review procedures. It will also obviate the need for separate and isolated interventions such as national REC registries or clinical trial registries, as these can be generated as transactional outputs of the system. The harmonized procedures and possibility of single submission will facilitate multi-site research. Sharing of resources and expertise among RECs on the platform will enhance resilience. An e-EC system developed in India and a Regional Health research portal developed by the WHO South-East Asia office offer proof of concepts to demonstrate the feasibility of developing and using such systems. The proposed solution is ambitious but feasible. Developing the proposed system will be a vital cost-effective investment in national health infrastructure to strengthen the research ecosystem and accelerate delivery of improved healthcare innovations by reducing unnecessary delays in conducting research. To maximize benefits, concurrent efforts are needed to build researchers' capacity and enhance the quality and efficiency of human reviews of the research proposals by REC.

### **Human Gene Therapy**

Volume 35, Issue 17-18 / September 2024

<https://www.liebertpub.com/toc/hum/35/17-18>

[New issue; No digest content identified]

### **Humanitarian Practice Network**

<https://odihpn.org/>

*Featured Publications*

[No new digest content identified]

### **Human Vaccines & Immunotherapeutics** (formerly Human Vaccines)

Volume 20 Issue 1, 2024

<https://www.tandfonline.com/toc/khvi20/20/1?nav=tocList>

*Selected Content*

[Reviewed earlier]

### **Immunity**

Sep 10, 2024 Volume 57 Issue 9 p1995-2250

<https://www.cell.com/immunity/current>

*Voices*

#### **Microbes and metabolites in immunity**

Eran Elinav, et al.

The immune system has a vital, albeit complex, relationship with the microbes residing within us, one that we are only beginning to understand. We asked investigators what they felt were the fundamental challenges we currently face in unraveling the impacts of microbes and their metabolites on host immunity and to discuss key opportunities toward achieving future insights and innovation.

### **Infectious Agents and Cancer**

<http://www.infectagentscancer.com/>

[Accessed 21 Sep 2024]

[No new digest content identified]

### **Infectious Diseases of Poverty**

<http://www.idpjournals.com/content>

[Accessed 21 Sep 2024]

[No new digest content identified]

### **International Health**

Volume 16, Issue 5, September 2024

<https://academic.oup.com/inthealth/issue/16/5>

[Reviewed earlier]

### **International Human Rights Law Review**

Volume 13 (2024): Issue 1 (Jun 2024):

<https://brill.com/view/journals/hrlr/13/1/hrlr.13.issue-1.xml>

#### ***Special Issue on Inter-State Communications***

*Table of Contents*

[Reviewed earlier]

### **International Journal of Community Medicine and Public Health**

Vol. 11 No. 9 (2024): September 2024

<https://www.ijcmph.com/index.php/ijcmph/issue/view/116>

[Reviewed earlier]

### **International Journal of Epidemiology**

Volume 53, Issue 4, August 2024

<https://academic.oup.com/ije/issue/53/4>

[Reviewed earlier]

### **International Journal of Human Rights in Healthcare**

Volume 17 Issue 3 2024

<https://www.emerald.com/insight/publication/issn/2056-4902/vol/17/iss/3>

*Table of contents*

[Reviewed earlier]

### **JAMA**

September 17, 2024, Vol 332, No. 11, Pages 857-942

<https://jamanetwork.com/journals/jama/currentissue>

*Viewpoint*

#### **Smallpox ReadinessModern Strategies Against an Ancient Disease**

Lawrence O. Gostin, JD; Shalini Singaravelu, MSc; Noreen Hynes, MD, MPH

JAMA. 2024;332(11):873-874. doi:10.1001/jama.2024.8614

This Viewpoint highlights the potential for unintentional or deliberate release of variola virus (smallpox), discusses current medical countermeasures for smallpox, and calls for greater flexibility from the US and its partners in developing safe, reliable, affordable, and equitable countermeasures.

### **JAMA Health Forum**

September 2024, Vol 5, No. 9

<https://jamanetwork.com/journals/jama-health-forum/issue>

[Reviewed earlier]

### **JAMA Pediatrics**

September 2024, Vol 178, No. 9, Pages 847-956

<https://jamanetwork.com/journals/jamapediatrics/currentissue>

[Reviewed earlier]

### **JBIR Evidence Synthesis**

August 2024 - Volume 22 - Issue 8

<https://journals.lww.com/jbisrir/Pages/currenttoc.aspx>

[Reviewed earlier]

### **Journal of Adolescent Health**

September 2024 Volume 75 Issue 3 p375-52

<https://www.jahonline.org/current>

[Reviewed earlier]

## **Journal of Artificial Intelligence Research**

Vol. 80 (2024)

<https://www.jair.org/index.php/jair>

*Contents*

[Reviewed earlier]

## **Journal of Community Health**

Volume 49, Issue 5 October 2024

<https://link.springer.com/journal/10900/volumes-and-issues/49-5>

### **Association between Socioeconomic Status and Vaccination Hesitancy, Reluctancy and Confidence among Asian-Americans Living in the State of New Jersey**

Brijesh Rana, Humberto R. Jimenez, Navaneeth Narayanan

Original Paper Open access 16 July 2024 Pages: 829 - 834

### **Vaccination Motivators and Deterrents Among Undervaccinated Older Adults in North Dakota**

Andrea L. Huseth-Zosel, Heather Fuller, Paul J. Carson

Original Paper 13 April 2024 Pages: 848 - 856

### **Association of Maternal Cervical Cancer Screening Adherence with Adolescent HPV Vaccination Among Adolescent-Mother Pairs**

Adino Tesfahun Tsegaye, John Lin, Rachel L. Winer

Original Paper 14 March 2024 Pages: 857 - 868

## **Journal of Current Medical Research and Opinion**

*...a peer-reviewed, international journal for the rapid publication of original research on new and existing drugs and therapies, and post-marketing investigations. Equivalence, safety and efficacy/effectiveness studies are especially encouraged.*

Vol. 7 No. 01 (2024), January 2, 2024 , Page 1988-1996

<https://www.cmro.in/index.php/jcmro/issue/view/75>

[Reviewed earlier]

## **Journal of Development Economics**

Volume 170 September 2024

<https://www.sciencedirect.com/journal/journal-of-development-economics/vol/170/suppl/C>

[Reviewed earlier]

## **Journal of Empirical Research on Human Research Ethics**

Volume 19 Issue 3, July 2024

<http://journals.sagepub.com/toc/jre/current>

### ***Special Issues in Research and IRB/REC Functioning, Including the use of AI***

[Reviewed earlier]

## **Journal of Epidemiology & Community Health**

August 2024 - Volume 78 - 8

<https://jech.bmj.com/content/78/8>

[Reviewed earlier]

**Journal of Evidence-Based Medicine**

Volume 17, Issue 2 Pages: 237-467 June 2024

<https://onlinelibrary.wiley.com/toc/17565391/current>

[Reviewed earlier]

**Journal of Global Ethics**

Volume 20, Issue 1 (2024)

<http://www.tandfonline.com/toc/rjge20/current>

[Reviewed earlier]

**Journal of Health Care for the Poor and Underserved (JHCPU)**

Volume 35, Number 3, August 2024

<https://muse.jhu.edu/issue/52935>

*Table of Contents*

[Reviewed earlier]

**Journal of Immigrant and Minority Health**

Volume 26, Issue 4 August 2024

<https://link.springer.com/journal/10903/volumes-and-issues/26-4>

[Reviewed earlier]

**Journal of Immigrant & Refugee Studies**

Volume 22, 2024 \_ Issue 3

<https://www.tandfonline.com/toc/wimm20/current>

[Reviewed earlier]

**Journal of International Development**

Volume 36, Issue 6 Pages: 3-2669 August 2024

<https://onlinelibrary.wiley.com/toc/10991328/current>

[Reviewed earlier]

**Journal of Medical Ethics**

September 2024 - Volume 50 - 9

<http://jme.bmj.com/content/current>

[Reviewed earlier]

**Journal of Patient-Centered Research and Reviews**

Volume 11, Issue 1 (2024)

<https://institutionalrepository.aah.org/jpcrr/>

[Reviewed earlier]

### **The Journal of Pediatrics**

Volume 272 September 2024

<https://www.sciencedirect.com/journal/the-journal-of-pediatrics/vol/272/suppl/C>

[New issue; No digest content identified]

### **Journal of Pharmaceutical Policy and Practice**

Volume 17, Issue 1 (2024) Issue 1

<https://www.tandfonline.com/toc/jppp20/17/1>

[Reviewed earlier]

### **Journal of Public Health Management & Practice**

September/October 2024 - Volume 30 - Issue 5

<https://journals.lww.com/jphmp/pages/currenttoc.aspx>

*Commentary*

**[Measles Back to the Future: Chicago's Current Measles Outbreak Demands the Creation of Federally Managed Isolation Housing Reminiscent of the Origin Story of the Vaccines for Children Program](#)**

Fricchione, Marielle J.; Nguyen, David C.; Nash, Colleen B.; More

Journal of Public Health Management and Practice. 30(5):647-648, September/October 2024.

### **Journal of Public Health Policy**

Volume 45, issue 3, September 2024

<https://link.springer.com/journal/41271/volumes-and-issues/45-3>

[Reviewed earlier]

### **Journal of the Royal Society – Interface**

September 2024 Volume 21 Issue 218

<https://royalsocietypublishing.org/toc/rsif/current>

[Reviewed earlier]

### **Journal of Travel Medicine**

Volume 31, Issue 6, August 2024

<https://academic.oup.com/jtm/issue>

[Reviewed earlier]

### **Journal of Virology**

Volume 98 • Number 6 • June 2024

<http://jvi.asm.org/content/current>

[Reviewed earlier]

### **The Lancet**

Sep 21, 2024 Volume 404 Number 10458 p1077-1170, e4

<https://www.thelancet.com/journals/lancet/issue/current>

*Series*

*Respiratory Syncytial Virus 2024*

**Severe respiratory syncytial virus infection in children: burden, management, and emerging therapies**

Natalie I Mazur, Mauricio T Caballero, Marta C Nunes

*Respiratory Syncytial Virus 2024*

**Respiratory syncytial virus vaccination and immunoprophylaxis: realising the potential for protection of young children**

Clint Pecenka, et al.

**The Lancet Child & Adolescent Health**

Sep 2024 Volume 8 Number 9 p611-706, e7-e11

<https://www.thelancet.com/journals/lanchi/issue/current>

[Reviewed earlier]

**Lancet Digital Health**

Sep 2024 Volume 6 Number 9 e601-e672

<https://www.thelancet.com/journals/landig/issue/current>

[Reviewed earlier]

**Lancet Global Health**

Sep 2024 Volume 12 Number 9 e1370-e1559

<https://www.thelancet.com/journals/langlo/issue/current>

[Reviewed earlier]

**Lancet Infectious Diseases**

Sep 2024 Volume 24 Number 9 p935-1058, e540-e601

<https://www.thelancet.com/journals/laninf/issue/current>

[Reviewed earlier]

**Lancet Public Health**

Sep 2024 Volume 9 Number 9 e635-e708

<https://www.thelancet.com/journals/lanpub/issue/current>

[Reviewed earlier]

**Lancet Respiratory Medicine**

Sep 2024 Volume 12 Number 9 p655-742, e52-e56

<https://www.thelancet.com/journals/lanres/issue/current>

[Reviewed earlier]

**Maternal and Child Health Journal**

Volume 28, Issue 9 September 2024

<https://link.springer.com/journal/10995/volumes-and-issues/28-9>

[New issue; No digest content identified]

## **Medical Decision Making (MDM)**

Volume 44 Issue 6, August 2024

<http://mdm.sagepub.com/content/current>

[Reviewed earlier]

## **The Milbank Quarterly**

*A Multidisciplinary Journal of Population Health and Health Policy*

Volume 102, Issue 3 Pages: 517-821 September 2024

<https://onlinelibrary.wiley.com/toc/14680009/current>

[New issue; No digest content identified]

## **Molecular Therapy**

Sep 04, 2024 Volume 32 Issue 9 p2801-3194

<https://www.cell.com/molecular-therapy/current>

[Reviewed earlier]

## **Nature**

Volume 633 Issue 8030, 19 September 2024

<https://www.nature.com/nature/volumes/633/issues/8029>

*Editorial* 17 Sep 2024

### **[Unearthing 'hidden' science would help to tackle the world's biggest problems](#)**

Tens of thousands of studies evaluating government programmes are collecting dust in institutional vaults. Sharing them could benefit everyone.

*World View*

### **[Stop delaying action on antimicrobial resistance — it is achievable and affordable](#)**

Ensuring that clinics in low- and middle-income countries are well-stocked with high-quality antibiotics could help physicians to treat millions of people each year and slow the spread of drug resistance.

Ramanan Laxminarayan

*Comment* 17 Sep 2024

### **[Tackling antimicrobial resistance needs a tailored approach — four specialists weigh in](#)**

Ahead of a United Nations meeting on the global challenge of drug-resistant infections, Nature asked health-care experts in emerging economies to describe what would address the issue in their country or region most effectively.

Senjuti Saha, Ana Cristina Gales, Nour Shamas

## **Nature Biotechnology**

Volume 42 Issue 9, September 2024

<https://www.nature.com/nbt/volumes/42/issues/9>

*Editorial* 05 Sept 2024

### **[Pandemic preparedness demands proper prioritization](#)**

We have learned many lessons from COVID-19, but how to get vaccines to low- and middle-income countries effectively isn't one of them.

## **Nature Communications**



<https://www.nature.com/subjects/health-sciences/ncomms>  
(Accessed 21 Sep 2024)  
[No new digest content identified]

### **Nature Genetics**

Volume 56 Issue 9, September 2024

<https://www.nature.com/ng/volumes/56/issues/9>

*Perspective* 05 Aug 2024

#### **[Promoting equity in polygenic risk assessment through global collaboration](#)**

The clinical use of current polygenic risk scores (PRSs) might widen global health disparities, as their portability to diverse groups is limited, emphasizing the need for global collaboration to develop PRSs that perform equitably across the world.

Iftikhar J. Kullo

### **Nature Human Behaviour**

Volume 8 Issue 8, August 2024

<https://www.nature.com/nathumbehav/volumes/8/issues/8>

[Reviewed earlier]

### **Nature Medicine**

Volume 30 Issue 9, September 2024

<https://www.nature.com/nm/volumes/30/issues/9>

*Editorial* 17 Sep 2024

#### **[Countering the impact of the climate crisis on health will require data](#)**

As drastically rising global temperatures threaten the health and wellbeing of populations, solutions that drive policy action must be based on scientific evidence of which strategies work in different scenarios.

*Review Article* 03 Sept 2024

#### **[Advancing global antibiotic research, development and access](#)**

Tackling antimicrobial resistance will require a sustainable research and development ecosystem for antibiotic development, alongside strategies for responsible use and global access.

Laura J. V. Piddock, Yewande Alimi, Peter Beyer

### **Nature Reviews Drug Discovery**

Volume 23 Issue 9, September 2024

<https://www.nature.com/nrd/volumes/23/issues/9>

[Reviewed earlier]

### **Nature Reviews Genetics**

Volume 25 Issue 9, September 2024

<https://www.nature.com/nrg/volumes/25/issues/9>

[Reviewed earlier]

### **Nature Reviews Immunology**

Volume 24 Issue 9, September 2024

<https://www.nature.com/nri/volumes/24/issues/9>  
[Reviewed earlier]

### **New England Journal of Medicine**

Volume 391 No. 11 September 19, 2024  
<https://www.nejm.org/toc/nejm/medical-journal>  
[New issue; No digest content identified]

### **NEJM Evidence**

Volume 3 No. 9 September 2024  
<https://evidence.nejm.org/toc/evid/current>  
*NEJM Evidence, a new monthly digital journal from NEJM Group, presents innovative original research and fresh, bold ideas in clinical trial design and clinical decision-making.*  
[Reviewed earlier]

### **njp Vaccines**

<https://www.nature.com/npjvaccines/>  
[Accessed 21 Sep 2024]  
[Reviewed earlier]

### **Pediatrics**

Volume 154, Issue 3 September 2024  
<https://publications.aap.org/pediatrics/issue/154/3>  
[Reviewed earlier]

### **PharmacoEconomics**

Volume 42, Issue 9 September 2024  
<https://link.springer.com/journal/40273/volumes-and-issues/42-9>  
[Reviewed earlier]

### **PLoS Biology**

<https://journals.plos.org/plosbiology/>  
(Accessed 21 Sep 2024)

#### **[Promoting reusable and open methods and protocols \(PRO-MaP\) can improve methodological reporting in the life sciences](#)**

Sofia Batista Leite, Matthew A. Brooke, Annamaria Carusi, Andy Collings, Pierre Deceuninck, Jean-François Dechamp, Bronwen Dekker, Elisa De Ranieri, Emma Ganley, Annalisa Gastaldello, Fanglian He, Marcel LaFlamme, Ingrid Langezaal, James Morris, David Pamies, Monica Piergiovanni, Bernd Pulverer, David Sadler, Caroline Shamu, Vivian Siegel, Marco Straccia, Tracey L. Weissgerber  
Perspective | published 19 Sep 2024 PLOS Biology  
<https://doi.org/10.1371/journal.pbio.3002835>

### **PLoS Genetics**

<https://journals.plos.org/plosgenetics/>  
(Accessed 21 Sep 2024)

[No new digest content identified]

## **PLoS Global Public Health**

[https://journals.plos.org/globalpublichealth/search?sortOrder=DATE\\_NEWEST\\_FIRST&filterStartDate=2021-10-01&filterJournals=PLOSGlobalPublicHealth&q=&resultsPerPage=60](https://journals.plos.org/globalpublichealth/search?sortOrder=DATE_NEWEST_FIRST&filterStartDate=2021-10-01&filterJournals=PLOSGlobalPublicHealth&q=&resultsPerPage=60)

(Accessed 21 Sep 2024)

### **[Health system interventions and responses to anti-microbial resistance: A scoping review of evidence from 15 African countries](#)**

Jacob Albin Korem Alhassan, Clement Kamil Abdallah

Research Article | published 18 Sep 2024 PLOS Global Public Health

<https://doi.org/10.1371/journal.pgph.0003688>

### **[Civil society activism for Africa's vaccine and local manufacturing agenda: Can mpox be the test case?](#)**

Nicaise Ndembi, George Kimathi, Achal Prabhala, Jackline Kiarie

Opinion | published 17 Sep 2024 PLOS Global Public Health

<https://doi.org/10.1371/journal.pgph.0003738>

## **PLoS Medicine**

<https://journals.plos.org/plosmedicine/>

(Accessed 21 Sep 2024)

[No new digest content identified]

## **PLoS Neglected Tropical Diseases**

<http://www.plosntds.org/>

(Accessed 21 Sep 2024)

[No new digest content identified]

## **PLoS One**

<http://www.plosone.org/>

[Accessed 21 Sep 2024]

### **[Influenza vaccine hesitancy among healthcare workers in a Northeastern province in Thailand: Findings of a cross-sectional survey](#)**

Manash Shrestha, Penchan Pradubmook Sherer, Seung Chun Paek, Kriengkrai Prasert, Sutthinan Chawalchitiporn, Prabda Praphasiri

Research Article | published 19 Sep 2024 PLOS ONE

<https://doi.org/10.1371/journal.pone.0310761>

### **[Effect of vaccine dose intervals: Considering immunity levels, vaccine efficacy, and strain variants for disease control strategy](#)**

Samiran Ghosh, Malay Banerjee, Amit K. Chattopadhyay

Research Article | published 19 Sep 2024 PLOS ONE

<https://doi.org/10.1371/journal.pone.0310152>

## **PLoS Pathogens**

<http://journals.plos.org/plospathogens/>

[Accessed 21 Sep 2024]

[No new digest content identified]

**PNAS - Proceedings of the National Academy of Sciences of the United States**

September 17, 2024 vol. 121 no. 38

<https://www.pnas.org/toc/pnas/121/38>

[New issue; No digest content identified]

**PNAS Nexus**

Volume 3, Issue 8, August 2024

<https://academic.oup.com/pnasnexus/issue/3/8>

[Reviewed earlier]

**Prehospital & Disaster Medicine**

Volume 39 - Issue 2 - April 2024

<https://www.cambridge.org/core/journals/prehospital-and-disaster-medicine/latest-issue>

[Reviewed earlier]

**Preventive Medicine**

Volume 187 October 2024

<https://www.sciencedirect.com/journal/preventive-medicine/vol/187/suppl/C>

[New issue; No digest content identified]

**Proceedings of the Royal Society B**

September 2024 Volume 291 Issue 2030

<https://royalsocietypublishing.org/toc/rspb/current>

[Reviewed earlier]

**Public Health**

Volume 235 Pages 1-218 (October 2024)

<https://www.sciencedirect.com/journal/public-health/vol/235/suppl/C>

[Reviewed earlier]

**Public Health Ethics**

Volume 17, Issue 1-2, April/July 2024

<http://phe.oxfordjournals.org/content/current>

[Reviewed earlier]

**Public Health Genomics**

2024, Vol. 27, No. 1

<https://karger.com/phg/issue/27/1>

[Reviewed earlier]

**Public Health Reports**

Volume 139 Issue 5, September/October 2024

<https://journals.sagepub.com/toc/phrg/139/5>

*Topical Review*

**[Infectious Diseases Among People Experiencing Homelessness: A Systematic Review of the Literature in the United States and Canada, 2003-2022](#)**

Caroline J. Waddell PhD, Carlos S. Saldana MD, Megan M. Schoonveld MPH

**Qualitative Health Research**

Volume 34 Issue 10, August 2024

<https://journals.sagepub.com/toc/QHR/current>

[Reviewed earlier]

**Research Ethics**

Volume 20 Issue 3, July 2024

<http://journals.sagepub.com/toc/reab/current>

[Reviewed earlier]

**Reproductive Health**

<http://www.reproductive-health-journal.com/content>

[Accessed 21 Sep 2024]

[No new digest content identified]

**Revista Panamericana de Salud Pública/Pan American Journal of Public Health (RPSP/PAJPH)**

<https://www.paho.org/journal/en>

*Latest Articles*

18 Sep 2024

**[State of HIV costing in Latin America and the Caribbean: a systematic literature review](#)**

Review | English |

18 Sep 2024

**[We must not remain blind to equity: lessons to be learned from the COVID-19 pandemic in the Americas](#)**

Special report | Spanish |

**Risk Analysis**

Volume 44, Issue 9 Pages: 1977-2311 September 2024

<https://onlinelibrary.wiley.com/toc/15396924/current>

[Reviewed earlier]

**Risk Management and Healthcare Policy**

<https://www.dovepress.com/risk-management-and-healthcare-policy-archive56>

[Accessed 21 Sep 2024]

[Reviewed earlier]

## **Science**

Volume 385| Issue 6715| 20 Sep 2024  
<https://www.science.org/toc/science/current>  
[New issue; No digest content identified]

## **Science and Engineering Ethics**

Volume 30, Issue 5 October 2024  
<https://link.springer.com/journal/11948/volumes-and-issues/30-5>  
[Reviewed earlier]

## **Science Translational Medicine**

Volume 16| Issue 765| 18 Sep 2024  
<https://www.science.org/toc/stm/current>  
[New issue; No digest content identified]

## **Scientific Reports**

<https://www.nature.com/srep/articles?type=article>  
[Accessed 21 Sep 2024]  
[No new digest content identified]

## **Social Science & Medicine**

Volume 358 October 2024  
<https://www.sciencedirect.com/journal/social-science-and-medicine/vol/358/suppl/C>  
*Research article* Open access  
[\*\*Identifying vulnerabilities in essential health services: Analysing the effects of system shocks on childhood vaccination delivery in Lebanon\*\*](#)  
Sharif A. Ismail, Andrada Tomoaia-Cotisel, Aya Noubani, Fouad M. Fouad, ... Josephine Borghi  
Article 117260

## **Systematic Reviews**

<https://systematicreviewsjournal.biomedcentral.com/articles>  
[Accessed 21 Sep 2024]  
[No new digest content identified]

## **Theoretical Medicine and Bioethics**

Volume 45, Issue 5 October 2024  
<https://link.springer.com/journal/11017/volumes-and-issues/45-5>  
[Reviewed earlier]

## **Travel Medicine and Infectious Diseases**

Volume 61 September–October 2024  
<https://www.sciencedirect.com/journal/travel-medicine-and-infectious-disease/vol/61/suppl/C>  
[Reviewed earlier]

## **Tropical Medicine & International Health**

Volume 29, Issue 9 Pages: i-iv, 757-847 September 2024

<https://onlinelibrary.wiley.com/toc/13653156/current>

[Reviewed earlier]

## **Vaccine**

Volume 42, Issue 24 24 October 2024

<https://www.sciencedirect.com/journal/vaccine/vol/42/issue/24>

*Research article* Abstract only

### **[Evaluation of interventions to improve timely hepatitis B birth dose vaccination among infants and maternal tetanus vaccination among pregnant women in Nigeria](#)**

Florence A. Kanu, Catherine Freeland, Ugochukwu Uzoechina Nwokoro, Yahaya Mohammed, ... Rania

A. Tohme

Article 126222

*Research article* Abstract only

### **[Persistence of immunity in children aged 2 months and 7 months – 5 years old after primary immunization with 13-valent pneumococcal conjugate vaccine](#)**

Guifan Li, Tao Ren, Hao Zhang, Jing Ti, ... Jiankai Liu

Article 126209

*Research article* Open access

### **[Using health literacy principles to improve understanding of evolving evidence in health emergencies: Optimisation and evaluation of a COVID-19 vaccination risk-benefit calculator](#)**

Carissa Bonner, Melody Taba, Michael Anthony Fajardo, Carys Batcup, ... John C.B. Litt

Article 126296

*Research article* Abstract only

### **[Cost-effectiveness of vaccinating adults aged 60 years and older against respiratory syncytial virus](#)**

David W. Hutton, Lisa A. Prosser, Angela M. Rose, Kerra Mercon, ... Michael Melgar

Article 126294

*Research article* Abstract only

### **[Relationship between parental acceptance of the COVID-19 vaccine and attitudes towards measles vaccination for children: A cross-sectional study](#)**

Xiaoting Jiang, Jingxuan Wang, Conglu Li, Eng Kiong Yeoh, ... Ka Chun Chong

Article 126068

*Research article* Open access

### **[Knowledge gap of human monkeypox among high-risk individuals receiving preexposure vaccination in Taiwan](#)**

Tsu-Hsuan Hu, Chiao-Yun Tou, Yi-Hsuan Lee, Hao-Hsiang Chang, ... Chia-Wen Lu

Article 126111

## **Vaccines**

<https://www.mdpi.com/journal/vaccines>

[Accessed 21 Sep 2024]

*Open Access Review*

## **Navigating the Evolving Landscape of COVID-19: Strategies to Increase Vaccine Confidence and Improve Vaccination Rates in the United States**

by James A. Mansi, Heather R. Hensler, Rachel Dawson, Reed Tuckson and Todd Wolynn  
Vaccines 2024, 12(9), 1072; <https://doi.org/10.3390/vaccines12091072> - 19 Sep 2024

### *Abstract*

The COVID-19 pandemic has had a significant impact on every individual in the United States. The launch of the COVID-19 vaccines is estimated to have averted millions of deaths and reduced over 18 million COVID-19-related hospitalizations. In September 2023, the updated 2023–2024 COVID-19

*Open Access Article*

## **Progress with the Second Dose Measles Vaccine Introduction and Coverage in the WHO African Region**

by Balcha G. Masresha, Messeret E. Shibeshi, Gavin B. Grant, Cynthia Hatcher and Charles S. Wiysonge  
Vaccines 2024, 12(9), 1069; <https://doi.org/10.3390/vaccines12091069> - 18 Sep 2024

### *Abstract*

Introduction: To achieve global and regional measles elimination objectives, the World Health Organization (WHO) recommends coverage of 95% or higher with two doses of measles-containing vaccine. A second dose of measles-containing vaccine (MCV) is typically administered in the second year of life after [

## **Value in Health**

September 2024 Volume 27 Issue 9 p1175-1310

<https://www.valueinhealthjournal.com/current>

[Reviewed earlier]

## **World Development**

Volume 180 August 2024

<https://www.sciencedirect.com/journal/world-development/vol/180/suppl/C>

[Reviewed earlier]

.....  
.....

## ***Contents [click to move among sections]***

:: [\*Milestones, Perspectives\*](#)

:: [\*WHO\*](#)

:: [\*Organization Announcements\*](#)

:: [\*Journal Watch\*](#)

:: [\*Pre-Print Servers\*](#)

.....  
.....

## ***Pre-Print Servers***

### **arxiv**

<https://arxiv.org/>

[Accessed 21 Sep 2024]

[Filter: Genomics; Neurons and Cognition; Populations and Evolution; Other Quantitative Biology; General Economics]



## **Opportunities and challenges of mRNA technologies in development of Dengue Virus Vaccine**

Xiaoyang Liu, Daniel Salmon

[Submitted on 17 Sep 2024]

Dengue virus (DENV) is a mosquito-borne virus with a significant human health concern. With 390 million infections annually and 96 million showing clinical symptoms, severe dengue can lead to life-threatening conditions like dengue hemorrhagic fever (DHF) and dengue shock syndrome (DSS). The only FDA-approved vaccine, Dengvaxia, has limitations due to antibody-dependent enhancement (ADE), necessitating careful administration. The recent pre-approval of TAK-003 by WHO in 2024 highlights ongoing efforts to improve vaccine options. This review explores recent advancements in dengue vaccine development, emphasizing potential utility of mRNA-based vaccines. By examining current clinical trial data and innovations, we aim to identify promising strategies to address the limitations of existing vaccines and enhance global dengue prevention efforts.

## **Gates Open Research**

<https://gatesopenresearch.org/browse/articles>

[Accessed 21 Sep 2024]

[No new digest content identified]

## **medRxiv**

<https://www.medrxiv.org/content/about-medrxiv>

[Accessed 21 Sep 2024]

[Filter: All articles]

## **Human papillomavirus vaccination at the national level in Tunisia: a cost-effectiveness analysis using a comparative modeling study.**

Oumaima Laraj, Beya Benzina, Ahlem Gzara, Amira Kebir, Kaja Abbas, Slimane Ben Miled

medRxiv 2024.09.17.24313756; doi: <https://doi.org/10.1101/2024.09.17.24313756>

## **A systematic review of psychological factors influencing attitudes and intentions toward, and uptake of, Covid-19 vaccines in adolescents**

Angie Pitt, Richard Amlôt, Catherine Heffernan, G. James Rubin, Louise E. Smith

medRxiv 2024.09.17.24313392; doi: <https://doi.org/10.1101/2024.09.17.24313392>

## **First imported Cases of MPXV Clade Ib in Goma, Democratic Republic of the Congo: Implications for Global Surveillance and Transmission Dynamics**

Daniel Mukadi-Bamuleka, Eddy Kinganda-Lusamaki, Noella Mulopo-Mukanya, Adrienne Amuri-Aziza, Áine O'Toole, Brigitte Modadra-Madakpa, Guy Mutombo Ndongala, Emmanuel Hasivirwe Vakaniaki, Sydney Merritt, Cris Kacita, Gaston Lubambo Maboko, Jean-Claude Makangara-Cigolo, Michel Ngimba, Emmanuel Lokilo, Elisabeth Pukuta-Simbu, Gradi Luakanda, Tavia Bodisa-Matamu, Zephania Paluku Kalimuli, Prince Akil-Bandali, Sifa Kavira, Daan Jansen, Adèle Kavira Kamaliro, Emile Muhindo-Milonde, Jeriel Mufungizi, Yves Birindwa Hamisi, Hugo Kavunga, Olivier Tshiani, Sabin S. Nundu, Laurens Liesenborghs, Nicole A. Hoff, Jean Nachega, Robert Shongo, Ahidjo Ayoub, Genay Pilarowski, Alain Kakule Mangolopa, Amos Kiuka Ebondo, Nicola Low, Souradet Y. Shaw, Sam Wilkinson, Sofonias Kifle Tessema, Lorenzo Subissi, Eric Delaporte, Koen Vercauteren, Tony Wawina-Bokalanga, Anne W Rimoin, Martine Peeters, Nicholas Loman, Andrew Rambaut, Jean-Jacques Muyembe-Tamfum, Lisa E. Hensley, Jason Kindrachuk, Placide Mbala-Kingebeni, Steve Ahuka-Mundeke

medRxiv 2024.09.12.24313188; doi: <https://doi.org/10.1101/2024.09.12.24313188>

## **OSF Pre-prints**

<https://osf.io/preprints/discover?provider=OSF&subject=bepress%7C%20Life%20Sciences>  
*[Provider Filter: OSF Pre-prints Subject filters: Medicine and Health Sciences Format Filter: Pre-]*  
[No new digest content identified]

### **Wellcome Open Research**

<https://wellcomeopenresearch.org/browse/articles>  
[Accessed 21 Sep 2024]  
*Selected Research*  
[No new digest content identified]

\* \* \* \*

### **Think Tanks**

**Brookings** [to 21 Sep 2024]  
<http://www.brookings.edu/>  
*Research*  
*No new digest content identified.*

**Center for Global Development** [to 21 Sep 2024]  
<https://www.cgdev.org/>  
*All Research*  
*CGD NOTES*  
**The Global Roadmap for Action on the Care Economy**  
Kelsey Harris et al.  
September 19, 2024

The Global Roadmap for Action on the Care Economy (GRAC) provides a strategic framework that maps the global care landscape and its opportunities, highlights existing data and gaps in measurement, supports coordination and de-siloing efforts, and provides insights to inform future advocacy, research...

**Chatham House** [to 21 Sep 2024]  
<https://www.chathamhouse.org/>  
*Selected Analysis, Comment, Events*  
*No new digest content identified.*

**Council on Foreign Relations** [to 21 Sep 2024]  
<https://www.cfr.org/media/news-releases>  
*New Releases [Selected]*  
*No new digest content identified.*

**CSIS** [to 21 Sep 2024]  
<https://www.csis.org/>  
*Reports [Selected]*  
*No new digest content identified.*

**Kaiser Family Foundation** [to 21 Sep 2024]  
[https://www.kff.org/search/?post\\_type=press-release](https://www.kff.org/search/?post_type=press-release)  
*Newsroom*  
*No new digest content identified.*

**McKinsey Global Institute** [to 21 Sep 2024]  
<https://www.mckinsey.com/mgi/overview>  
*Latest Research*  
*No new digest content identified.*

**ODI [Overseas Development Institute]** [to 21 Sep 2024]  
<https://odi.org/en/publications/>  
*Publications [Selected]*  
*No new digest content identified.*

**Pew Research Center** [to 21 Sep 2024]  
<https://www.pewresearch.org/>  
*Latest Publications [Selected]*  
*No new digest content identified.*

**Rand** [to 21 Sep 2024]  
<https://www.rand.org/pubs.html>  
*Published Research [Selected]*  
*No new digest content identified.*

**Urban Institute** [to 21 Sep 2024]  
<https://www.urban.org/publications>  
[\*\*New Research Publications - Selected\*\*](#)

**World Economic Forum** [to 21 Sep 2024]  
<https://agenda.weforum.org/press/>  
*Media [Selected]*  
[\*\*Sustainable Development Impact Meetings 2024 to Drive Transformative Action on the SDGS\*\*](#)

News 18 Sep 2024

:: The World Economic Forum's Sustainable Development Impact Meetings 2024 are taking place on 23 to 27 September in New York.

:: The meetings will focus on reinvigorating multistakeholder momentum on the Sustainable Development Goals through innovative cross-sector partnerships.

:: More than 1,000 global leaders will come together to exchange perspectives and accelerate the concerted collaboration needed to advance progress on the UN objectives by 2030.

:: Follow the Sustainable Development Impact Meetings 2024 [here](#)

.....  
.....

## Public Consultations/Call for Inputs/Call for Papers

### Call for Public Comment: General Principles on Plan, Design, and Analysis of Pharmacoepidemiological Studies that Utilize Real-World Data for Safety Assessment of Medicines.

ICH [International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use]

The guideline will focus on non-interventional pharmacoepidemiological studies using Real-World Data (RWD) and will include basic principles that may apply to these studies when real-world data elements are included.

*Public consultation dates [announced to date]:*

ANVISA, Brazil - Deadline for comments by 24 August 2024

FDA, United States - Deadline for comments by 3 September 2024

MFDS, Republic of Korea - Deadline for comments by 15 July 2024

MHLW/PMDA, Japan - Deadline for comments by 28 July 2024

NMPA, China - Deadline for comments by 12 October 2024

TFDA, Chinese Taipei - Deadline for comments by 30 September 2024

*	*	*	*
*	*	*	*

***Vaccines and Global Health: The Week in Review*** is a service of the Center for Vaccine Ethics and Policy ([CVEP](#)) / GE2P2 Global Foundation, which is solely responsible for its content.

.....

*Copyright GE2P2 Global Foundation 2024. Some Rights Reserved.*

*This work is licensed under the Creative Commons Attribution 4.0 International License. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/> or send a letter to Creative Commons, PO Box 1866, Mountain View, CA 94042, USA.*

*Under the terms of this license, you may copy, redistribute, and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that the GE2P2 Global Foundation endorses any specific organization, products, or services. The use of the GE2P2 Global Foundation logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons license.*

.....

CVEP is a program of the [GE2P2 Global Foundation](#) whose purpose and mission is to advance ethical and scientific rigor in research and evidence generation for governance, policy and practice in health, human rights action, humanitarian response, heritage stewardship, education and sustainable development. The Foundation serves governments, international agencies, INGOs, civil society organizations (CSOs), commercial entities, consortia and alliances.

Support for this service is provided by the [Bill & Melinda Gates Foundation](#); the [Bill & Melinda Gates Medical Research Institute](#), and industry resource members Janssen/J&J, Pfizer, Sanofi US, and Takeda, (list in formation).

Support is also provided by a growing list of individuals who use this membership service to support their roles in public health, clinical practice, government, NGOs and other international institutions, academia and research organizations, and industry.

*	*	*	*
*	*	*	*